 
 
 
 
 
Protocol No.: APL-CP0514 
 
 
 
 
An Open Label, Single and Multiple Ascen ding Dose Study to Assess the Safety, 
Tolerability, Pharmacokinetics a nd Pharmacodynamics of APL-2  
as an Add-On to Standard of Care in Subjects  
with Paroxysmal Nocturnal Hemoglobinuria (PNH). 
Phase: 1 
Version: Version 4.0, Amendment 7 
Date: June 15, 2017 
 
  
 
 
Confidentiality Statement 
This document is confidential. It contains proprietary informat ion of Apellis Pharmaceutical, Inc. Any viewing or 
disclosure of such information that is not authorized in writin g by Apellis Pharmaceutical, Inc is strictly 
prohibited. Such information may be used solely for the purpose  of reviewing or performing this study. 
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 2 of 72 1. SYNOPSIS 
Protocol Number APL-CP0514 
Protocol Version 
and Date  Version 4.0 Amendment 7 
June 15 , 2017 
Compound APL-2 
Study Phase and 
Type  Phase 1, open-label, prospective, non-randomized, single and 
multiple ascending dose, first -in-human study in patients with PNH 
Study Objectives The primary objectives of the study are to assess the safety, 
tolerability and pharmacokinetics of single and multiple subcutaneous 
(SC) doses of APL -2 in subjects with paroxysmal nocturnal 
hemoglobinuria (PNH) who are still anemic after treatment with 
eculizumab (Soliris®). 
An exploratory objective of the study is to assess the 
pharmacodynamics (PD) of single and multiple SC doses of APL-2 
when administe red to PNH patients. See “Pharmacodynamic 
Assessment” below.  
Study Population Subjects will: 
x be male and female (using contraception as specified in the 
protocol) at least 18 years of age  
x have a diagnosis of PNH and still be anemic (after being 
treated with eculizumab (Soliris®) for at least 3 months prior to 
screening. 
Number of Subjects The study is planned to enroll a pproximately 15 subjects across  4 
Cohorts . Cohorts 1-3 will comprise 2 subjects in each cohort. Cohort 4 
will enroll sufficient subjects to ensure at least 6 subjects complete 28 
days  dosing with APL-2. Subjects may participate in more than one 
cohort . Additional cohorts may be enrolled if it is deemed appropriate 
by the Sponsor in consultation with the Safety Monitoring Commi ttee 
(SMC)  to repeat a dose level or to study an interim dose level. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 3 of 72 Inclusion Criteria x Male or Female 
x At least 18 years of age 
x Weigh >55 kg  
x Diagnosed with PNH 
x On treatment with eculizumab (Soliris®) for at least 3 months 
x Hb <10 g/dL at screening OR have received at least one transfusion 
within 12 months prior to screening 
x Platelet count of >30,000/mm3 
x Absolute neutrophil count >500/mm3 
x Women of child- bearing potential (WOCBP) must have a negative 
pregnancy test at screening and must a gree to use protocol defined 
methods of contraception for the duration of the study 
x Males must agree to use protocol defined methods of contracepti on and 
agree to refrain from donating sp erm for the duration of the st udy 
x Willing and able to give informed consent 
Exclusion Criteria x Active bacterial infection 
x Known infection with hepatitis B, C or HIV 
x Hereditary complement deficiency 
x History of bone marrow transplantation 
x Participation in any other invest igational drug trial or exposu re to other 
investigational agent, device or procedure within 30 days 
x Evid ence  of  QT cF prol ong a tion defin ed  as > 4 50 ms  f or males  an d >470 
ms for females at screening 
x Creatinine clearance (CrCl) <50 mL/min (Cockcroft-Gault formula ) at 
screening 
x Breast-feeding women 
x History of meningococcal disease 
x No vaccination against N. meningitides  t y p e s  A ,  C ,  W ,  Y  a n d  B  
(administered as two separate vac cinations), Pneumococcal conju gate 
vaccine or Pneumococcal polysaccharide vaccine 23 (PCV13 or PPS V23, 
respectively) and Haemophilus influenzae  Type B (Hib) vaccination within 
2 years prior to Day 1 dosing.   
Endpoints The primary endpoints of the study are the number and severity of TEAEs 
and pharmacokinetics parameters of APL-2 following administrati on of 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 4 of 72 single and multiple SC doses. 
 Exploratory pharmacodynamics markers include:
 
x Complement (e.g., CH50, AH50, and C3) levels 
x C3 deposition on RBC cells 
x Hemoglobin 
x Reticulocytes 
x Lactate dehydrogenase (LDH) 
x Bilirubin 
x Clonal distribution of PNH vs normal bone marrow derived cells 
Planned Dose 
Levels  Planned doses will be as follows: 
Cohort Planned dosing schedule (Amendment 5) 
1 25 mg on Day 1 then 5 mg/da y from Day 29 to Day 56 
2 50 mg on Day 1 then 30 mg/d ay from Day 29 to Day 56 
3 180 mg/day from Day 1 to Day 28 
4 270 mg/day from Day 1 to D ay 729* with optional 
intrasubject escalation up to 360  mg/day after Day 28** 
*Subjects may initially receive APL- 2 for 28 days (Part 1) and if there is evidence of 
clinical benefit they may continue to receive APL-2 until Day 84 (Part 2A) and if 
there is ongoing evidence of clinical benefit they may continue to recei ve APL -2 
until Day  364 (Part 2B). If subjects continue to have clinical benefit they may receive 
APL-2 until Day 729 (Part 2C).     
** Individual patient dose escalat i o n  u p  t o  a  d o s e  o f  3 6 0  m g / d a y  m a y  o c c u r  in 
subjects who have a sub -optimal hematological response but acceptable 
tolerability.  
Repeat of any cohort or the addition of interim dose level may be 
added, as determined by the Sponsor in consultation with the Safety 
Monitoring Committee  (SMC) , depending on the safety results from 
the prior cohort(s).  
Study Design This is a prospective, non-rando mized, single and multiple asce nding 
dose study. Four Cohorts are planned for evaluation. Subjects in 
Cohorts 1 and 2 will receive a single dose of APL -2 followed by a 28-
day waiting period before receiving daily doses for 28 days. Subjects 
in Cohort 3 will receive multiple doses (daily dosing) for 28 days. 
Subjects in Cohort 4 will receive mul tiple doses (daily dosing) for 28 
days and if, following review of available safety and PD data a vailable 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 5 of 72   within the first 28 days, subjec ts have shown evidence of clini cal 
benefit s, as assessed by the Investigator and Sponsor, they may 
progress to Part 2 A of the study and continue to receive daily doses 
of APL 2 until Day  84 and to Part 2B of the study and continue to 
receive daily doses of APL-2 until Day 36 4. If subjects continue to 
have clinical benefit they  may receive APL-2 until Day 729 (Part 2C).  
Subjects may participate in more than one cohort. 
Safety will be assessed throughout the study; serial blood samp les 
and urine samples will be collect ed for these assessments. Bloo d 
samples will also be collected for the PK assessment of APL -2. 
Additional s amples for assessment of PD will also be collected. 
Interim PK analyses may be performed to reconsider the sampling  
time points and dose escalations as the study progresses.  
For prior study design including the dosing schedule for Cohorts 1 to  
3, refer to prior versions of the protocol.  
Subjects in Cohort 4 will initially receive 270 mg SC APL- 2 daily for 28 
days.  Subjects will be entered into the study at Visit 2 (Day 1) at a 
time designated by the PI and will receive daily SC doses of APL- 2 at 
Visits 2 to 29 (Days 1 to 28). The first 4 daily SC doses of APL- 2 (Visits 
2 to 5) as well as doses at Visits 9, 16 and 23 will be administ ered at 
the clinical site. Subjects will remain in the clinic for at least 4 hours 
after the first dosing at Visit 2. 
Following  ongoing review of available safety, PK and PD data by the 
Investigator and Sponsor, subjects showing evidence of clinical 
benefit may progress to Part 2A , then to Part 2B and then to Part 2C  
of the study and may continue to receive daily doses of APL-2 until 
Day 84 , then until Day 364, and then  until Day 729. Doses will be 
administered off -site at the subject’s home, workplace, or other 
location convenient to the subject, with the exception of Visit s 30, 44, 
58, 72, 86, 114, 142, 170, 198, 226, 254, 282,  310, 338, 366, 367, 368, 
369, 370, and 371  (Days 29, 43, 57, 71, 85, 113, 141, 169, 197, 225, 
253, 281, 309, 337, 420, 476, 532, 616,  and 729 respectively) and with 
the exception of up to 3 additional site Vi sits, if individual dose 
escalation occurs for subjects administered >270 mg/day SC APL-2, 
where dosing will occur at the clinical site. After conclusion of the 
Part 2 C treatment period on Visit 371 (Day 729 ), subjects will return 
to the clinical site for final st udy procedures at an Exit Visi t on Day 
785 See Study Flow Chart. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 6 of 72 TABLE OF CONTENTS 
1. SYNOPSIS ...................................................................................................................... ........... 2  
AMENDMENT 1 ................................................................................................................... ............ 9  
AMENDMENT 2 ................................................................................................................... .......... 12  
AMENDMENT 3 ................................................................................................................... .......... 13  
AMENDMENT 4 ................................................................................................................... .......... 15  
AMENDMENT 5 ................................................................................................................... .......... 18  
AMENDMENT 6 ................................................................................................................... .......... 19  
2. STUDY FLOW CHART ............................................................................................................ 2 2 
3. ABBREVIATIONS ................................................................................................................. ... 28 
4. INTRODUCTION................................................................................................................... ... 30 
4.1 Background ..................................................................................................................... 30  
4.1.1  Paroxysmal Nocturnal Hemoglobinuria ................................................................... 30  
4.1.2  APL-2 ....................................................................................................................... 3 0 
4.2 Rationale ......................................................................................................................... 37  
4.2.1  Purpose of the Study ............................................................................................... 37  
4.2.2  Dose Selection ......................................................................................................... 37  
4.3 Risk/Benefit ..................................................................................................................... 39  
5. STUDY OBJECTIVES AND ENDPOINTS ............................................................................... 40  
5.1 Study Objectives ............................................................................................................. 40 
5.2 Study Endpoints.............................................................................................................. 4 0 
6. STUDY DESIGN .................................................................................................................. .... 41  
7. SUBJECT SELECTION ........................................................................................................... 4 2 
7.1 Inclusion Criteria ............................................................................................................ . 42 
7.1.1  Approved methods of contraception ........................................................................ 42  
7.2 Exclusion Criteria ............................................................................................................  42 
8. STUDY TREATMENTS ........................................................................................................... 43  
8.1 Allocation to Treatment ................................................................................................... 43  
8.2 Blinding ...................................................................................................................... ..... 43  
8.3 Treatments Administered ............................................................................................... 43  
8.3.1  Drug supplies ........................................................................................................... 43  
8.3.2  Planned Dose Levels ............................................................................................... 44  
8.3.3  Drug Administration ................................................................................................. 45  
8.3.4  Additional Dose Levels ............................................................................................ 45  
8.4 Concomitant Medications ............................................................................................... 45  
8.4.1  Vaccinations ............................................................................................................ 45  
8.4.2  Prophylactic antibiotics ............................................................................................ 46  
9. STUDY PROCEDURES .......................................................................................................... 46  
9.1 Screening (Visit 1) .......................................................................................................... 46 
9.2 Treatment Period (Visits 2 to 36) .................................................................................... 47  
9.2.1  Dosing Period (Visits 2 to 365) ................................................................................ 47  
9.2.2  Exit Visits (Visit 372) ................................................................................................ 48  
9.2.3  Unscheduled Follow-up Visits ................................................................................. 48  
9.2.4  Scheduled End of Study .......................................................................................... 48  
9.3 Dose Escalation and Periodic Safety Review ................................................................ 48  
9.3.1  Safety Monitoring Committee .................................................................................. 49  
9.4 Removal of Subjects from the Study .............................................................................. 50  
10. ASSESSMENTS ................................................................................................................... ... 50 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 7 of 72 10.1 Safety Assessments ..................................................................................................... 50  
10.1.1  Body Height and Weight ........................................................................................ 50  
10.1.2  Physical Examination............................................................................................. 51  
10.1.3  Vital Signs .............................................................................................................. 51  
10.1.4  Electrocardiogram Monitoring ................................................................................ 51  
10.1.5  Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale ......... 51  
10.1.6  Clinical Laboratory Tests ....................................................................................... 52  
10.1.7  Injection Site Assessment ..................................................................................... 53  
10.2 Pharmacokinetic Assessments ..................................................................................... 53  
10.2.1  Blood Sampling and Processing ............................................................................ 53  
10.2.2  Analytical Method .................................................................................................. 54  
10.3 Pharmacodynamic Assessments ................................................................................. 54  
10.4 Blood Volume for Study Assessments ......................................................................... 55  
10.5 Pregnancy tests ............................................................................................................ 55  
11. ADVERSE EVENTS ................................................................................................................  55 
11.1 Definitions ................................................................................................................... .. 55 
11.2 Recording Adverse Events ........................................................................................... 56  
11.3 Assessment of Adverse Events .................................................................................... 56  
11.3.1  Intensity ................................................................................................................. 56  
11.3.2  Causality ................................................................................................................ 57  
11.3.3  Serious Adverse Event .......................................................................................... 58  
11.4 Reporting Serious Adverse Event ................................................................................ 58  
11.5 Adverse Events of Special Interest............................................................................... 59  
11.6 Unexpected Adverse Events or Unexpected Suspected Adverse Reactions .............. 59  
11.7 Treatment and Follow up of Adverse Events ............................................................... 60  
11.8 Pregnancy ..................................................................................................................... 60  
12. STATISTICS .................................................................................................................... ........ 60  
12.1 Sample Size Justification .............................................................................................. 60  
12.2 Statistical Analysis Methodology .................................................................................. 60  
12.2.1  Study Analysis Datasets ........................................................................................ 61  
12.3 Study Endpoints............................................................................................................ 61  
12.3.1  Efficacy Endpoint ................................................................................................... 61  
12.3.2  Safety Endpoints .................................................................................................... 61  
12.3.3  Pharmacokinetic Endpoints ................................................................................... 61  
12.4 Efficacy Analysis ........................................................................................................... 6 1 
12.5 Safety Analysis ............................................................................................................. 6 2 
12.5.1  Total Exposure ....................................................................................................... 62  
12.5.2  Adverse Events ...................................................................................................... 62  
12.5.3  Clinical Laboratory Tests ....................................................................................... 62  
12.5.4  Vital Signs .............................................................................................................. 62  
12.5.5  ECGs ..................................................................................................................... 63  
12.6 Handling of Dropouts and/or Missing Data ................................................................... 63  
12.7 Examination of Subgroups ........................................................................................... 63  
12.8 Enumerated Data.......................................................................................................... 63  
12.9 Pharmacokinetic Analysis ............................................................................................. 63  
12.10  Pharmacodynamic Analysis ......................................................................................... 64  
12.11  Antigenicity Analysis..................................................................................................... 64  
12.12  Interim Analysis ............................................................................................................ 6 4 
12.12.1  Safety (optional) ................................................................................................... 64  
13. ADMINISTRATIVE CONSIDERATIONS ................................................................................. 64  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 8 of 72 13.1 Direct Access to Source Data/Documents ................................................................... 64  
13.2 Quality Control and Quality Assurance ........................................................................ 65  
13.2.1  Monitoring .............................................................................................................. 65  
13.3 Ethics ........................................................................................................................ .... 65  
13.3.1  Ethical Conduct of the Study ................................................................................. 65  
13.3.2  Institutional Review Board/Ethic Committee ......................................................... 65  
13.3.3  Subject Information and Consent .......................................................................... 66  
13.3.4  Confidentiality ........................................................................................................ 66  
13.3.5  ClinicalTrials.gov .................................................................................................... 66  
13.3.6  Termination of Study.............................................................................................. 66  
13.4 Data Handling and Record Keeping ............................................................................. 66  
13.5 Protocol Amendments .................................................................................................. 67  
13.6 Report Format ............................................................................................................... 67  
13.7 Finance and Insurance ................................................................................................. 67  
13.8 Publication Policy.......................................................................................................... 67  
14. REFERENCES..................................................................................................................... .... 68  
15. APPENDIX 1: FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY 
(FACIT) FATIGUE SCALE ................................................................................................ 69  
16. APPENDIX 2: ASSESSMENT OF LOCAL INJECTION SITE REACTIONS ........................... 72  
 
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 9 of 72 AMENDMENT 1 
Revision 1:  Inclusion Criteria #1: The uppe r age limit of 65 years for inc lusion will be removed. 
Rationale:  Although the median age of the 1610 patients enrolled in the i nternational PNH 
registry (as of June 30, 2012) was 42 years old; the range is 3  to 99 years old ( Schrezenmeier, 
2014 ). This update to the inclusion c riteria will allow collection of data on APL-2 across a wider 
range of the adult PNH population and better support subsequent  clinical studies. 
Section updated: Section 7.1  
 Revision 2:  Inclusion Criteria #6 and #7: Hemoglobin (Hb) level and transf usion inclusion 
criteria were combined into a single criterion to allow patient s with Hb <10 g/dL at screening 
OR at least one transfusion within the last 12 months. 
Rationale:  The previous inclusion criteria requiring pre-transfusion Hb<1 0 g/dL at the last 
transfusion AND last transfusion within 12 months prior to scre ening is causing confusion. The 
pre-transfusion Hb value is not always available to the investi gator and a value of <10 g/dL is 
implicit as the criteria for transfusion in PNH subjects is gen erally Hb<10 g/dL. The addition of 
Hb <10 g/dL at screening ensures  that subjects are still anemic  despite treatment with Soliris® 
even if they have not received a transfusion in the past year. 
Section updated: Section 7.1  
 Revision 3:   Exclusion Criteria #7: Cre atinine clearance (CrCl) 
(Cockcroft-Gault formula) will be 
amended from <60 mL/min to <50 mL/min. 
Rationale:  Mild to moderate reduction in gl omerular filtration rate (GFR)  is commonly seen in 
the PNH patient population. Repor t from Phase III studies with Soliris® indicate that 65% of 
patients presented renal dysf unction (GFR <60 mL/min/1.73m2) at baseline with 21 % of 
patients being at the later stage of Chronic Kidney Disease (CK D) or kidney failure. Whereas 
approximately 30% of patients im prove after treatment with Soli ris® (mostly those with Stage 
1 or 2 CKD), close to 70% of pat ients do not improve and can ev en worsen ( Hillmen, 2010 ). 
This is of relevance as the target population for this current trial is patients who are not fully 
responding to Soliris®. A reducti on in the minimum CrCl require d for inclusion will allow 
patients with moderate reduction in GFR (CKD Stage 3A) to parti cipate in the study while 
more severe GFR reductions (CKD Stages 3B to 5) will continue t o be excluded. 
Section updated: Section 7.2  
   
 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 10 of 72 Revision 4:  Multiple doses for cohort 2, 3 and 4 will be updated as follow s: 
 
 Single SC dose 
(day 1) 
Unchanged Multiple SC dose 
(days 29 to 56) 
Original Protocol Multiple SC dose 
(days 29 to 56) 
Amendment 1 
Cohort 1  25 mg APL-2  5 mg APL-2 / day  5 mg APL-2 / day  
Cohort 2  50 mg APL-2 10 mg APL-2 / day 30 mg APL-2 / day 
Cohort 3  100 mg APL-2 20 mg APL-2 / day 90 mg APL-2 / day 
Cohort 4  200 mg APL-2 40 mg APL-2 / day 180 mg APL-2 / day 
Rationale:  The doses were updated based on emerging safety, pharmacokinet ic and 
pharmacodynamics data from ongoing studies in healthy subjects currently conducted in 
Australia summarized in section 4 .1.2.2.2. Rationale for this c hange is described in the 
updated Section 4.2.2 of this document.  
Sections Updated: Sections 4.1.2.2.2, 4.2.2 and 8.3.2  
 Revision 5:  Description of the investigational product has been updated to  include a 
lyophilized product formulation to be used for the higher doses . 
Rationale:  For reasons of stability and fl exibility, the drug product is now being produced as 
lyophilized vials that are reconstituted just prior to administ ration. This new presentation will 
be used for the repeated dose portion of the trial at the highe r doses. 
Section updated: Section 8.3.1  
 
Revision 6:  Removal of pre-defined stopping rules and creation of an indep endent Safety 
Monitoring Committee (SMC).  
Rationale:  Previously, the transition to m ultiple dosing and escalation t o the next cohort 
would occur only after review of safety data for both  subjects in the preceding cohort. This is 
problematic as both patients in a cohort would need to be sched uled to commence dosing in 
parallel on the same day, which is unfeasible given the low num bers of patients with PNH. 
Otherwise, it would result in ev ery patient having a different window between single and 
multiple dosing and consequently being enrolled into study for different lengths of time. This 
creates a logistical challenge fo r the sites and makes comparis on of data across patients very 
difficult.  
The new dose escalation scheme will follow the same schedule as  previously stipulated (i.e. 28 
days between single and multiple dosing). However: 
The transition to multiple dosing within a subject will occur a utomatically once the subject has 
completed the 28-day waiting period.  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 11 of 72 Dose escalation and initiation of a subsequent cohort will only  occur once both subjects in the 
preceding cohort have completed t he single-dose 28-day waiting period. 
The above transitions would not occur if modification, or stopp ing of the study, is proposed by 
the SMC following their regular review. 
An independent SMC will be convened to include at minimum a hem atologist with PHN 
experience and an infectious disease specialist. The SMC decisi ons will not be guided by pre-
defined stopping rules as they will have total authority to sto p any dose escalation (or the 
study) at any time because of any safety concern beyond the pre -defined incidence of SAEs or 
Grade 3 toxicities. The SMC will meet every 4 weeks and review all available cumulative 
safety, PK and PD data. The SMC meeting will not always coincid e with the dose escalations 
but this high frequency review of cumulative data will provide assurance of ongoing patient 
safety. 
Section Updated: Section 9.3  
 Revision 7:  Addition of an Adverse Events of special interest section. 
Rationale:  This section includes AE of scientific and medical concern spe cific to the product or 
program where ongoing monitoring and rapid communication by the  Investigator to the 
Sponsor may be appropriate. In addition, occurrence of these AE s will be presented separately 
to the SMC. 
Section Updated: Section 11.5  
 
Additional Revisions:  Editorial changes have been mad e throughout the protocol for c larity or 
corrections. 
 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 12 of 72 Amendment 2 
Revision 1:  Inclusion Criteria #3: The weig ht and BMI criteria have been r evised. 
Rationale: The weight and BMI restriction h as significantly limited the nu mber of patients 
eligible to participate in this clinical study. Preliminary pha rmacokinetic (PK) data from 
ongoing studies suggests that the impact of this update will be  negligible with respect to 
exposure. This update to the inc lusion criteria will allow coll ection of data on APL-2 across a 
wider range of the adult PNH population and better support subs equent clinical studies. 
Section updated: Section 7.1  
 
Revision 2:  Clarification with respect to r eporting of Adverse Events (AEs ) of special interest. 
Rationale: The section has been updated to include thrombosis as an AE of special interest 
and to reflect the fact that these events will be reported prom ptly and only within 24 hours if 
they fulfill the SAE criteria. 
Section Updated: Section 11.5  
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 13 of 72 AMENDMENT 3 
Revision 1: Protocol updated to remove singl e dosing period for Cohorts 3 a nd 4.  
Rationale:  
1. The first in human single dose study in healthy volunteers has been completed and 
doses up to and including 1440 mg have been tested providing sa fety and PK data to 
support moving directly into multiple dosing in this study.  
2. Recruitment of patients will be less problematic if the period of single dosing and its 
associated monitoring is removed as the study duration will be shorter 
Sections updated:  All relevant sections (including the Study Flow Chart) through out the 
protocol (other than stated objectives) have been updated to re move the single dosing period 
for Cohorts 3 and 4. 
 Revision 2: Multiple doses for cohorts 3 and 4 will be updated as follows: 
 Multiple SC dose 
(days 29 to 56) 
Amendment 1 Multiple SC dose 
(days 1 to 28) 
Amendment 3 
Cohort 1  5 mg APL-2 / day N/A 
Cohort 2  30 mg APL-2 / day N/A 
Cohort 3  90 mg APL-2 / day 180 mg APL-2 / day 
Cohort 4  180 mg APL-2 / day 270 mg APL-2 / day 
Rationale:  The doses were updated based on emerging safety, pharmacokinet ic and 
pharmacodynamics data from ongoing studies in healthy subjects currently conducted in 
Australia where multiple doses up to 270 mg/day for 28 days hav e been administered to 
healthy volunteers. This data is summarized in section 4.1.2.2. 2. Rationale for this change is 
described in the updated Section 4.2.2 of this document.  
Sections Updated: Sections 4.1.2.2.1, 4.1.2.2.2, 4.2.2 and 8.3.2  
 Revision 3: Prophylactic immunization requirement at screening updated to i nclude N. 
meningitides type B (in addition to types A, C, W, Y), Pneumoco ccal conjugate vaccine or 
Pneumococcal polysaccharide vacc ine 23 (PCV13 or PPSV23, respec tively) and Haemophilus 
influenzae Type B (Hib) vaccinat ion within 2 years prior to Day  1 dosing. Boosters for N. 
meningitides types A, C, W, Y and B (administered as two separa te injections) will also be 
administered during the study. 
Rationale: This update provides broader prophylactic coverage against a ra nge of infectious 
organisms to which subjects might be susceptible to during comp lement inhibition and allows 
use of Penicillin V rather than Augmentin (see revision 4 below ). 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 14 of 72 Section updated:  Sections 4.3 and 7.11 
 Revision 4: Prophylactic antibiotics updated to include Penicillin V as fir st line therapy 
commencing on Day 1 of dosing. 
Rationale: The amended immunization program at screening allows the use of  penicillin V 
rather than Augmentin as first line prophylaxis. Penicillin V i s generally better tolerated by 
subjects for long term administration i.e. greater than 7-10 da ys.  
Section updated:  Sections 4.3 7.11 and 8.4 
 
Revision 5: Updates to address points that required clarification  
1. Updated to include LDH at screen ing as well as other time point s as previously omitted 
in error 
2. Updated to include GGT as part of clinical chemistry testing as  previously omitted in 
error. 
3. Blood volume table updated to show blood volumes relating to up dated protocol i.e. 
removal of single dosing period  
Rationale: Editorial updates required for consistency and clarification 
Section updated:  Various throughout the document 
 
Revision 6: Drug presentation updated to ref lect new doses for Cohorts 3 an d 4  
Rationale: Increased doses require update to the Study Treatment sections of the protocol to 
reflect the correct presentation of APL-2 
Section updated:  Section 8 
 Revision 7: Statistical Section Updated 
Rationale: The Statistical Section of the protocol has been updated to be consistent with the 
Statistical Analysis Plan (SAP).  The SAP provides the detail ar ound the proposed statistical 
analyses and has also been updated to reflect the protocol amen dment. Information that was 
previously updated within the SA P has either been removed or up dated within the body of 
the protocol to ensure consistency between documents. 
Section updated:  Section 12 
  
 APL-2
Ascending Dose / First in Human / PNH Add-on to SOC
Apellis Pharmaceuticals, Inc. Protocol Number: APL-CP0514
V4.0 Amendment 7
Effective: 15-JUN-2017
PROT_ APL-CP0514_Amendment 7_June 15th, 2017 - CONFIDENTIAL Page 15of 72AMENDMENT 4 
Background: 
Since the initiation of this stu dy, emerging data from this and  other clinical studies has 
become available providing additional evidence of pharmacologic al activity of APL-2 at doses 
≥ 180 mg/day. 
In a multiple dose healthy volun teer study (APL-CP1014) a signi ficant decrease in complement 
mediated hemolytic activity was observed in all APL-2 treated s ubjects dose levels of 180 and 
270 mg/d. The inhibition of hemolytic activity observed at 180 mg/d was partial in all subjects 
but was essentially complete in 3 out of 4 subjects at 270 mg/d  
In this study (APL-CP0514) two subjects have completed cohort 3  dosing receiving a dose of 
180 mg/d for 28 days. Both subjec ts showed clinical improvement s, consistent with related 
changes in blood biomarkers.  
 
 
 
 
 
 
  
In a study in PNH patients who are not receiving eculizumab (PA DDOCK), two subjects have 
received APL-2 doses of 180 mg/d for 28 days.  
 
 
 
 
 
 
 
 
These initial data suggest that daily SC administration of APL- 2 at doses of 180 mg/d or higher 
can provide sustained inhibition of hemolytic activity in PNH p atients. APL-2 may, therefore, 
provide clinical benefit to subj ects with PNH who have not rece ived eculizumab treatment or 
have a suboptimal response to eculizumab treatment.  
Longer term APL-2 dosing and increased subject numbers are requ ired to obtain additional 
safety and evidence of activity data to support the design Phas e II/III studies. 
Administration of APL-2 at the proposed dose for Cohort 4 (270 mg/d) is expected to result in 
APL-2 exposure in subjects (C max and AUC) lower than what has been deemed safe for up to 3 
months of SC administration in m onkeys. In clinical studies, th e same dose has already been 
shown to be well-tolerated for 28 days in a healthy volunteer s tudy. Based on this data we PPD
PPD
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 16 of 72 propose to extend administration of APL-2 to subjects in Cohort  4 for up to 84 days (12 weeks) 
if clinical benefits of the treatment can be established within  the first 28 days of dosing. 
 Revision 1: Increase number of subjects in Cohort 4 to at least N=6 to comp lete 28 days of dosing. 
Rationale:  To obtain additional safety data and evidence of activity at a pharmacological dose. 
Sections updated: Synopsis and Sections 6 and 7. 
 
Revision 2: 
Allow for dosing period to be extended up to 84 days, contingen t on perceived benefits. 
Subjects in Cohort 4 will receive multiple doses (daily dosing)  for 28 days and if, following 
review of available safety and PD data, subjects have shown evi dence of clinical benefits as 
assessed by the Investigator and Sponsor, they may progress to Part 2 of the study and 
continue to receive daily doses of APL 2 until Day 84. 
Rationale:  To obtain long term safety data and evidence of activity at a p harmacological dose. 
Sections updated: Synopsis and Sections 2, 4.3, 6, 9.2 and 9.3 
 
Revision 3:  Subjects may participate in more than 1 cohort. 
Rationale:  The beneficial response was seen in the two subjects who recei ved APL-2 180 mg/d 
for 28 days may increase at the higher dose of 270 mg/d. Based on the effect observed and 
the availability of additional toxicology data to support dosin g beyond 28 days, participation in 
more than 1 cohort does not pose additional undue risk and has a reasonable likelihood of 
providing additional clinical benefits to patient. 
Sections updated: Synopsis and Sections 6 and 7 
Revision 4:  Inclusion Criterion #3: The Bod y Mass Index criterion has been  removed. 
Rationale:  The weight and BMI restriction has significantly limited the n umber of patients 
eligible to participate in this clinical study. Inclusion crite rion #3 had already been revised in 
Amendment 2 (August 12, 2015) based on PK data from ongoing stu dies at the time. Later, 
based on the data collected in the healthy volunteer studies, a  population PK model was 
developed to characterize the relationship between APL-2 serum concentrations with dose 
and time. Using the developed population PK model the possible relationships between PK 
concentration and subject charac teristics such as weight, BMI a nd gender have been explored. 
Based on the limited ranges, the impact of weight and BMI on ke y PK parameters appears to 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 17 of 72 be small. Amending the inclusion criteria to allow for subjects  with higher BMI and/or weight 
to be enrolled would provide use ful information to explore thes e covariates further. 
Sections updated: Synopsis and Section 7.1 
 Revision 5: Prophylactic immunization requirem ent for Pneumococcus at scree ning updated 
to include a dose of PCV 13 at l east 2 weeks prior to Day 1 fol lowed by a dose of PPSV23 at 
least 8 weeks later. 
Rationale: This update follows the Center fo r Disease Control and Preventi on’s (CDC) 
recommendations for Pneumococcal vaccine in patients with immun ocompromissing 
conditions. 
Section updated:  Sections 2, 4.3 and 8.4 (new section 8.4.1)  
 Additional Revisions:  Editorial changes have been mad e throughout the protocol for c larity or 
corrections. 
 APL-2
Ascending Dose / First in Human / PNH Add-on to SOC
Apellis Pharmaceuticals, Inc. Protocol Number: APL-CP0514
V4.0 Amendment 7
Effective: 15-JUN-2017
PROT_ APL-CP0514_Amendment 7_June 15th, 2017 - CONFIDENTIAL Page 18of 72AMENDMENT 5 
Background: On September 29, 2016, the SMC met to review all available safe ty data and make a decision 
on extension of dosing for subjects in Cohort 4. At that time, Cohorts 1, 2, and 3 had 
completed and six subjects had been enrolled into Cohort 4 (3 s ubjects receiving ongoing 
treatment with APL-2 and 3 subjects scheduled to commence treat ment during the month of 
October 2016). Subjects enrolled into Cohorts 3 (180 mg/day) an d 4 (270 mg/day) have 
experienced clinical benefit from daily APL-2 treatment.  
As of September 29, 2016, the first three subjects in Cohort 4 ()  h a d  
completed Part 1 and moved into Part 2 and had received treatme nt with APL-2 270 mg for 
51, 30, and 38 days, respectivel y. There were a total of three AEs that the investigators 
assigned as possibly related to APL-2 treatment: fatigue, myalg ia (30 mg APL-2) and brittle 
nails (180 mg APL-2). The SMC vot ed unanimously to extend the d uration of APL-2 
administration beyond 84 days for subjects in Cohort 4 who expe rience clinical benefit as 
evidenced by reduction in LD, in crease in Type III CD59 negativ e RBCs, reduction in blood 
transfusion requirement, reduction in reticulocytes, and/or pat ient’s perceived improvement 
in PNH symptoms. 
 Revision 1:  Subjects experiencing clinical benefit during the Part 2A trea tment period (Day 29 
to Day 84), may enter the Part 2B treatment period (Day 85 to D ay 364).  
Rationale:  If a subject experiences a meas ureable improvement in PNH symp toms during 
APL-2 treatment, it would be in the subject’s best interest to continue to receive APL-2 
treatment for as long as the imp rovement in symptoms continues.  Therefore, in the event 
that the Investigator deems that a subject experienced clinical  benefit during Part 2A, the 
subject will be invited to partic ipate in Part 2B, and after pr oviding informed consent, will 
continue to receive ongoing daily APL-2 administration for up t o Day 364. In the event that the 
Investigator deems that a subject did not experience adequate c linical benefit during Part 2A 
(or at any time during Part 2B), the subject will discontinue d aily APL-2 administration and will 
enter the Part 3 follow-up period. 
Sections updated: Synopsis and Sections 2, 4.1.2.1 .3, added 4.1.2.2.3, 4.2.2, 4.3 , 5.2, 6, 
8.3.1.2, 8.3.2, 8.3.3, 9.2, 9.2.1, 9.2.1.1, 9.2.1.2, 9.2.2, 9.2 .4, 9.3, 10.1.5, 10.1.7, 10.4, 10.5, 
12.10, 12.12, 12.12.1, and removed 12.12.2. 
 
Additional Revisions:  Editorial changes have been mad e throughout the protocol for c larity or 
corrections. 
  PPD
 APL-2
Ascending Dose / First in Human / PNH Add-on to SOC
Apellis Pharmaceuticals, Inc. Protocol Number: APL-CP0514
V4.0 Amendment 7
Effective: 15-JUN-2017
PROT_ APL-CP0514_Amendment 7_June 15th, 2017 - CONFIDENTIAL Page 19of 72AMENDMENT 6 
Background: 
Cohorts 1, 2, and 3 have completed and six subjects have been e nrolled into Cohort 4. All 6 
subjects have completed at least 28 days dosing with SC APL-2 2 70 mg/d.  
Subjects enrolled into Cohort 3 (180 mg/day) and Cohort 4 (270 mg/day) experienced clinical 
benefit from daily APL-2 treatme nt as evidenced by a reduction in LDH, an increase in Hb, an 
increase in Type III CD59 negative RBCs, and a reduction in ret iculocytes.  
 
 
  
In addition, the 9-month toxicol ogy study in cynomologous monke ys has been completed and 
final data from the 3-month interim necropsy and draft data fro m the final 9-month necropsy 
are available. The 6-month chronic dosing study in rabbits has also been completed and final 
data are available. The toxicolo gical findings in the chronic s tudies were comparable to those 
observed in the original 28 day IND study and it was concluded that 7 mg/kg/day remains a 
NOAEL. These pre-clinical observat ions support chronic administ ration of 360 mg APL-2/day in 
humans. 
As the study has recently been extended to allow dosing with AP L-2 for up to one year it is 
recognized that the requirement for research nurses to visit th e subjects and administer the 
APL-2 solution using hand-held syringes is inconvenient, and th at repeated SC injections may 
cause pain at the injection site. An ambulatory syringe pump (e .g. Crono Super PID), will be 
introduced to allow self administration of APL-2 by the subject . A new formulation of APL-2 
solution for SC injection in which the diluent is acetate-buffe red mannitol rather than 
dextrose has been developed. Thi s formulation allows storage at  2-8° C making it more 
suitable for use in an ambulatory setting. Relevant compatibili ty testing has been performed 
with the pump evaluating both the 5% dextrose and acetate-buffe red mannitol formulations. 
When the infusion pump is intr oduced the subjects will receive thorough training by research 
nurses and/or investigator site staff. Once patients are compet ent and confident, they will will 
be able to self-administ er APL-2 via the pump.  
Revision 1: The protocol is updated to allow intra-subject dose escalation up to 360 mg/day 
Rationale:  If a subject has demonstrated acceptable tolerability but sub- optimal 
haematological responses to daily  treatment with 270 mg APL-2, the investigator, in 
conjunction with the sponsor, w ill be able to increase the dail y dose of APL-2 up to 360 mg for 
that subject in order to improve the clinical outcome. 
Revision 2: Updated to include an ambulatory syringe pump for delivery of A PL-2 and the new 
formulation of APL-2 for SC injection  
Rationale:  It is inconvenient for APL-2 to be administered by a research nurse on a daily basis 
and hand-held syringes may cause more injection site pain than syringe infusion pumps.  PPD
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 20 of 72 Sections Updated: Synopsis and Sections 2, 4.1.2, 4.1.2.1.3, 4.2.2, 4.3, 8.3.1.1,  8.3.1.2, 8.3.2,  
8.3.3, 10.4 
 
AMENDMENT 7 
Background: 
All 6 subjects in Cohort 4 continued into Part 2B of the study and 5/6 are currently receiving 
SC APL-2 270 mg/d and continue to experience clinical benefit f rom daily APL-2 treatment. 
Therefore, it is proposed that study treatment with APL-2 be fu rther extended to 729 days. 
 
Revision 1:  Subjects who continue to experi ence clinical benefit during th e Part 2B treatment 
period (Day 85 to Day 364), may enter the Part 2C treatment per iod (Day 365 to Day 729), 
which follows a less frequest visit schedule.  
Rationale:  If a subject continues to experience improvement in PNH sympto ms during APL-2 
treatment, it would be in the su bject’s best interest to contin ue to receive APL-2 treatment 
for as long as the improvement in symptoms continues. Therefore , in the event that the 
Investigator deems that a subject experienced clinical benefit during Part 2B, the subject will 
be invited to participate in Part 2C, and after providing infor med consent, will continue to 
receive ongoing daily APL-2 administration for up to Day 729. I n the event that the 
Investigator deems that a subject did not experience adequate c linical benefit during Part 2B, 
the subject will discontinue daily APL-2 administration and wil l enter the Part 3 exit period.  
The visit schedule in Part 2C fo llows a less frequent schedule based on the safety experience 
and profile to date. 
Section Updated: Synopsis, Section 2, 4.3, 6, 8.3.2, 9.2.1, 9.2 .1.1, 9.2.1.2, 9.2.2, 9.2.4, 9.3, 
10.1.5, 10.4, 10.5. 
 Revision 2: Updated to include a new formula tion of APL-2 for SC injection.   
Rationale:  The Sponsor has developed a new formulation of APL-2 solution for SC injection in 
which the diluent is acetate-buffered sorbitol rather than dext rose. This formulations allows 
storage at 2-8° C making it more  suitable for use in an ambulat ory setting. Relevant 
compatibility testing has been per formed with the pump evaluati ng both the 5% dextrose and 
acetate-buffered formulations.  
Section Updated : Section 4.1.2, 8.3.1.1, and 8.3.1.2 
 Revision 3:  Clarification with respect to r eporting of Adverse Events (AEs ) of special interest. 
Rationale: The section has been updated to include injection site reaction s and infusion pump 
related events as an AE of special interest.  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 21 of 72 Section Updated: Section 11.5  
 Additional Revisions:  Editorial changes have been mad e throughout the protocol for c larity or 
corrections. 
 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 22 of 72 2. STUDY FLOW CHART 
Study Period Screen PART 1 - Multiple Dose (Daily) 
Study Week  -4 1 2 3 4 
Study Day -30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
Study Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
Informed Consent X  
Demographics X  
Medical, transfusion, an d thrombosis history X  
Review entry criteria X  
Vaccination. A X                             
Preventive antibiotic. B X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Physical examination. C X  
12-lead electrocardiogram. D X X X X X X  
APL-2 administration. E S S S S H H H S H H H H H H S H H H H H H S H H H H H H 
Injection site assessment. F X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant medications X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Vital sign measurements. G X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Urinalysis X X X X X  
Blood. I X X X X X X X X  
Pharmacokinetics. I X X X X X X X  
Anti-APL-2 Ab assay X X X X  
Lactate dehydrogenase X X X X X  
Hematology and chemistry.  X X X X X  
Serology (HIV, HBsAg and HCV). J X  
Reticulocyte count X X X X  
Haptoglobin X X X X  
Coagulation profile X X  
Complement profile (C3, CH50 and AH50) X X X X  
Flow cytometry for PNH X X X X  
Flow cytometry C3 deposition X X X X  
Th17/Treg Analysis X  
Free hemoglobin X X X X  
Ferritin, vitamin B12 folate X X X X  
Pregnancy (B-HCG) X  
Urine pregnancy test. K X X X X  
FACIT fatigue Scale X X  
Adverse events X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Thrombosis record (MAVE). L X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
See Study Flow Chart Footnotes below continuation flow chart 
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 23 of 72 Study Period Part 2A - Treatment (Daily from Day 29 to Day 84) 
 Study Week 5 6 7 and 8 9 and 10 11 and 12 
Study Day  29 30 to 35 36 to 42 43 44 to 56 57 58 to 70 71 72 to 84 
 Study Visit  30 31 to 36 37 to 43 44 45 to 57 58 59 to 71 72 73 to 85 
Informed Consent 
Demographics 
Medical, transfusion, and thrombosis history 
Review entry criteria 
Preventive antibiotic. B X X X X X X X X X 
Physical examination. C X X 
12-lead electrocardiogram. D X X X X 
APL-2 administration. E S H H S H S H S H 
Injection site assessment. F X X X X X X X X X 
Concomitant medications X X X X X X X X X 
Vital sign measurements. G X X X X X X X X X 
Urinalysis X X X X 
Blood. I X X X X 
Pharmacokinetics. I X  X  X  X 
Anti-APL-2 Ab assay X X 
Lactate dehydrogenase X   X  X  X  
Hematology and chemistry.  X X X X 
Reticulocyte count X   X  X  X  
Haptoglobin X   X  X  X  
Coagulation profile X X X X 
Complement profile (C3, CH50 and AP50) X X X X 
Flow cytometry for PNH/C3 deposition X X X X 
Th17/Treg Analysis X         
Free Hemoglobin X   X  X  X  
Ferritin, vitamin B12 folate  X   X  X  X  
Urine pregnancy test. K X X X X 
FACIT fatigue Scale X X X 
Adverse events X X X X X X X X X 
Thrombosis record (MAVE) L X X X X X X X X X 
See Study Flow Chart Footnotes below continuation flow chart 
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 24 of 72 Study Period Part 2 B- Treatment (Daily fro m Day 85 to Day 364) - continued…  M 
 Study Week 13 to 16 17 to 20 21 to 24 25 to 28 29 to 32 33 to 36 
Study Day  85 86 to 112 113 114 to 140 141 142 to 168 169 170 to 196 197 198 to 224 225 226 to 252 
 Study Visit  86 87 to 113 114 115 to 141 142 143 to 169 170 171 to 197 198 199 to 225 226 227 to 253 
Informed Consent    
Demographics    
Medical, transfusion, an d thrombosis history    
Review entry criteria    
Preventive antibiotic. B X X X X X X X X X X X X 
Physical examination. C X    
12-lead electrocardiogram. D X X X X X X  
APL-2 administration. E S H S H S H S H S H S H 
Injection site assessment. F X X X X X X X X X X X X 
Concomitant medications X X X X X X X X X X X X 
Vital sign measurements. G X X X X X X X X X X X X 
Urinalysis X X X X X X  
Blood. I X X X X X X  
Pharmacokinetics. I X X  X  X  X X  
Anti-APL-2 Ab assay X  X X   
Lactate dehydrogenase X  X  X  X  X  X  
Hematology and chemistry.  X X X X X X  
Coagulation profile X X X X X X  
Reticulocyte count X  X  X  X  X  X  
Haptoglobin X  X  X  X  X  X  
Complement profile (C3, CH50 and AP50) X X X X X X  
Flow cytometry for PNH/C3 deposition X X X X X X  
Th17/Treg Analysis X            
Free Hemoglobin X  X  X  X  X  X  
Ferritin, vitamin B12 folate  X  X  X  X  X  X  
Urine pregnancy test. K X X X X X X  
FACIT fatigue Scale X  X X   
Adverse events X X X X X X X X X X X X 
Thrombosis record (MAVE) L X X X X X X X X X X X X 
See Study Flow Chart Footnotes below continuation flow chart 
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 25 of 72 Study Period … continued - Part 2B - Treatment (Daily from Day 85 to Day 364 ) M 
 Study Week 37 to 40 41 to 44 45 to 48 49 to 52 
Study Day  253 254 to 280 281 282 to 308 309 310 to 336 337 338 to 364 
 Study Visit  254 255 to 281 282 283 to 309 310 311 to 337 338 339 to 365 
Informed Consent 
Demographics 
Medical, transfusion, an d thrombosis history 
Review entry criteria 
Preventive antibiotic. B X X X X X X X X 
Physical examination. C X 
12-lead electrocardiogram. D X X X X 
APL-2 administration. E S H S H S H S H 
Injection site assessment. F X X X X X X X X 
Concomitant medications X X X X X X X X 
Vital sign measurements. G X X X X X X X X 
Urinalysis X X X X 
Blood. I X X X X 
Pharmacokinetics. I X X  X  X 
Anti-APL-2 Ab assay X X 
Lactate dehydrogenase X  X  X  X  
Hematology and chemistry.  X X X X 
Coagulation profile X X X X 
Reticulocyte count X  X  X  X  
Haptoglobin X  X  X  X  
Complement profile (C3, CH50 and AP50) X X X X 
Flow cytometry for PNH/C3 deposition X X X X 
Th17/Treg Analysis X        
Free Hemoglobin X  X  X  X  
Ferritin, vitamin B12 folate  X  X  X  X  
Urine pregnancy test. K X X X X 
FACIT fatigue Scale X   X 
Adverse events X X X X X X X X 
Thrombosis record (MAVE) L X X X X X X X X 
See study flow chart footnotes on next page   
 
 
 
 
 
 
 
 
 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 26 of 72  
Study Period … continued - Part 2C - Treatmen t (Daily from Day 365 to Day 72 9) M  Part 3 – Exit or ET 
(N) 
Study Week  56 60 68 80 92 104 112 
 Study Day  365   
(+/-7 days) 421 
(+/-7 days) 477 
(+/-7 days) 533 
(+/-14 days) 617 
(+/-14 days) 729 
(+/-14 days) 785 
(+/-14 days) 
 Study Visit  366 367 368 369 370 371 372 
Informed Consent    
Demographics    
Medical, transfusion, an d thrombosis history    
Review entry criteria    
Preventive antibiotic. B X X X X X X X 
Physical examination. C X  X 
12-lead electrocardiogram. D X X X X X X X 
APL-2 administration. E S S S S S S  
Injection site assessment. F X X X X X X X 
Concomitant medications X X X X X X X 
Vital sign measurements. G X X X X X X X 
Urinalysis X X X X X X X 
Blood. I X X X X X X X 
Pharmacokinetics. I X X X X X X X 
Anti-APL-2 Ab assay X X X X X X X 
Lactate dehydrogenase X X X X X X X 
Hematology and chemistry.  X X X X X X X 
Coagulation profile X X X X X X X 
Reticulocyte count X X X X X X X 
Haptoglobin X X X X X X X 
Complement profile (C3, CH50 and AP50) X X X X X X X 
Flow cytometry for PNH/C3 deposition X X X X X X X 
Th17/Treg Analysis X   X  X X 
Free Hemoglobin X X X X X X X 
Ferritin, vitamin B12 folate  X X X X X X X 
Urine pregnancy test. K X X X X X X X 
FACIT fatigue Scale X X X X X X X 
Adverse events X X X X X X X 
Thrombosis record (MAVE) L X X X X X X X 
See study flow chart footnotes on next page   
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 27 of 72  
FOOTNOTES: 
A. If Neisseria meningitidis  vaccine/s are administered during screening (up to Day –14), a  booster (for both vaccinations) should be administered after 2  
months. If Pneumococcal vaccination is required during screenin g, a dose of PCV13 will be administered at least two weeks prio r to Day 1 and a dose of 
PPSV23 will be administered at least 8 weeks later. 
B. Preventive antibiotics will be prescribed prior to Visit 2. Antibiotics will be taken from Visit 2 until 14 days after the last dose of APL-2. 
C. Full physical examination will be performed at the scheduled  time points indicated. A symptom-driven physical examination m ay be performed at other 
times, at the PI’s discretion. 
D. If done on a dosing day, electrocardiograms (ECGs) are to be  performed within 30 minutes after dosing. 
E. S = Administration at clinical site. H = Administration at s ubject’s home, workplace, or other location convenient to the s ubject. Treatment may be stopped 
at any time if the investigator a nd sponsor conclude that there  is no demonstration of clinical benefit to APL-2 continue admi nistration. Subjects may self-
administer the SC infusions at home, after receiving appropriat e training by a research nurse or other personnel. 
F. Injection site assessment will be performed within 30 minute s after APL-2 administration. After the subjects start to self- administer APL-2 via the pump, 
injection site reactions will no longer be evaluated by researc h personnel after at-home administrations. Subjects will be ins tructed to report any injection 
site reaction to the study coordinator. 
G. If done on a dosing day, vital signs will be measured within  2 hours prior to dosing and within 30 minutes after dosing. Af ter the subjects start to self-
administer APL-2 via the pump, vital signs will no longer be me asured before and after at-home administrations. 
H. Reserved – See note E. I. If done on a dosing day, bloo d samples will be taken pre-dos e with the exception that at Visit 2 only, a pharmacokinetic sa mple will be taken pre-dose and 
at 4 hours post-dose. 
J. Absence of Human immunodeficiency virus (HIV), Hepatitis B s urface antigen (HBsAg), and Hepatitis C virus (HCV), will be co nfirmed prior to APL-2 
administration. 
K. If done on a dosing day, urine pregnancy test should be comp leted for WOCBP prior to dosing.  
L. MAVE = Major Adverse Vascular Event. After the subjects star t to self-administer APL-2 via the pump, MAVE will no longer be  evaluated by research 
personnel during home visits. Subjects will be instructed to re port any events to the study coordinator. 
M. If the dose is increased to >270 mg/day, the subject will at tend the clinical site for safety visits every 2 weeks (instead  of every 4 weeks) for the first 
6 weeks after the dose increase i.e. up to an additional 3 clin ic visits. The extra clinic visits will be recorded as Unschedu led Visits and will alternate with the 
scheduled monthly visits. 
N. Subjects that discontinue dosing at any time during part 1, 2A, 2B, or 2C will move directly into Part 3 for the exit or ea rly termination visit.
 
 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 28 of 72 3. ABBREVIATIONS 
Abbreviations specific to this s tudy are listed. Pharmacokineti c (PK) parameter abbreviations 
and definitions may be found in Section 12.9 . 
 
ADL Activities of daily living  
AE Adverse event  
ALP Alkaline phosphatase  
ALT Alanine aminotransferase  
ANOVA  Analysis of variance  
API Active pharmaceutical ingredient  
aPTT  Activated partial thromboplastin time 
AST Aspartate aminotransferase  
BMI Body mass index  
BUN  Blood urea nitrogen  
qC Degrees Celsius  
Chem  Chemistry  
CFR Code of Federal Regulations  
CK Creatine  kinase 
CRF Case report form  
CS Clinically significant abnormality  
ECG Electrocardiogram  
qF Degrees Fahrenheit  
FDA Unites States Foods and Drug Administration  
FU Follow -up  
g Gram (s) 
GGT  Gamma glutamyl transferase  
GCP Good clinical practice  
HBsAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  
HED  Human equivalent dose 
Hem  Hematology  
hERG  Human ether -à-go-go-related gene 
HIV Human immunodeficiency virus  
HSA Human serum albumin  
IB Investigator’s brochure  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 29 of 72 ICH International Conferen ce on Harmonization  
kg Kilogram(s)  
L Liter(s)  
LDH Lactate dehydrogenase 
MAC  Membrane attack complex  
MAVE  Major Adverse Vascular Event  
MedDRA® Medical Dictionary for Regulatory Activities  
mg Milligram(s)  
mL Milliliter(s)  
μM Micromolar; micromoles/L  
NCS Not clinically significant  
NOEL  No observed effect level 
NOAEL  No observed adverse effect level  
PD Pharmacodynamic(s)  
PEG Polyethylene glycol  
PEG40  Polyethylene glycol (40 kDa nominal molecular weight)  
PI  Principal Investigator or designee  
PK Pharmacokinetic(s)  
PT Prothrombin time  
PNH  Paroxysmal nocturnal hemoglobinuria 
QTc Corrected QT interval  
QTcB  Bazett’s correction  
RBC Red blood cell  
SAE Serious adverse event  
SC Subcutaneous  
SAP Statistical Analysis Plan  
SMC  Safety Monitoring Committee  
SOP Standard operating procedure  
T½ Serum half-life 
TEAE  Treatment -emergent adverse event 
UA Urinalysis  
US Unites States of America  
WBC  White blood cell  
WHO  World Health Organization  
WOCBP  Woman of Child -Bearing Potential 
 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 30 of 72 4. INTRODUCTION 
4.1 Background 
This study is being conducted as the first in a series of studi es for the clinical development of 
APL-2. The trial will be conducted in compliance with the proto col, Good Clinical Practice (GCP), 
and applicable regulatory requirements. The subject population will be comprised of adult male 
and female subjects with paroxysmal nocturnal hemoglobinuria (P NH) under standard of care. 
4.1.1 Paroxysmal Nocturnal Hemoglobinuria 
PNH is an acquired, clonal, non-malignant hematological disease  characterized by complement-
mediated red blood cell (RBC) he molysis with or without hemoglo binuria, an increased 
susceptibility to thrombotic episodes, and/or some degree of bo ne marrow dysfunction. The 
onset of PNH is often insidious. Although there have been repor ts of spontaneous remission, 
the course of the disease is generally chronic and progressive.  
It has been known for many years that PNH is caused by compleme nt-mediated lysis of 
erythrocyte clones lacking funct ional CD55 and CD59 on their su rface to protect them against 
this process. As such, these erythrocytes are particularly susc eptible to the membrane attack 
complex (MAC) and have been shown to lyse readily in the presen ce of complement activation. 
The approval of eculizumab, a mo noclonal anti-C5 antibody inhib iting the formation of the 
MAC, as an effective treatment fo r PNH, has confirmed that inhi bition of the complement 
cascade is a valid therapeutic s trategy for addressing this ser ious condition. Any therapy that 
effectively inhibits MAC formati on is anticipated to be a plaus ible candidate treatment for PNH. 
However, inhibition of MAC formation does not appear to be suff icient to fully control the 
disease, as many PNH patients receiving eculizumab treatments s till suffer from anemia, with 
only roughly 13% of patients bei ng classified as complete respo nders, i.e., achieving transfusion 
independence and normal hemoglobin levels. Most of the patients  (53%) were classified as 
partial responders with decreased transfusion and lactate dehyd rogenase, and 33% of patients 
were poor responders, with unchang ed transfusion needs and pers istent symptoms ( DeZern, 
2013 ). 
Recent studies have suggested that significant opsonization of PNH erythrocytes by C3 
fragments is observed in patients receiving eculizumab treatmen t. This opsonization is believed 
to cause the removal of erythrocytes by the spleen and the live r, resulting in extravascular 
hemolysis. Extravascular hemolys is can be significant in a subs et of eculizumab-treated PNH 
patients and is considered to be the principal contributor to t he lack of complete eculizumab 
response in most patients. It is reasonable, therefore, to expe ct that a treatment able to inhibit 
both MAC formation and C3 opsonization will provide improved th erapeutic benefit to PNH 
patients compared to eculizumab. 
An overview of available informat ion regarding APL-2 follows be low. Details can  be found in the 
APL-2 Investigator’s Brochure ( Apellis Pharmaceuticals, 2016 ). 
4.1.2 APL-2 
APL-2 (PEGylated peptide) is a s mall 13-amino acid cyclic pepti de with 12 natural amino acids 
and a single synthetic amino acid (methyltryptophan) covalently  coupled via a linker to each 
end of a linear 40kDa polyethyle ne glycol (PEG40) chain, so the re are two peptide moieties per 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 31 of 72 molecule of APL-2. The peptide portion of the drug binds to com plement C3 and is a broad 
inhibitor of the complement cascade, a biological process that is part of innate immunity and is 
involved in multiple inflammatory processes. The PEGylation of the molecule imparts slower 
elimination from mammalian systems following administration.  
APL-2 injection (drug product) is a solution of APL-2 in 5% dex trose, acetate-buffered mannitol 
or acetate-buffered sorbitol for administration by subcutaneous  injection (SC). APL-2 is being 
developed for the treatment of paroxysmal nocturnal hemoglobinu ria (PNH). 
4.1.2.1   Nonclinical Data 
4.1.2.1.1  Pharmacology 
Primary pharmacology studies were performed with APL-2. Ex vivo  studies conducted with 
blood from PNH patients revealed that APL-2 can protect PNH red  blood cells (RBCs) from 
complement-mediated lysis and also prevents RBC opsonization by  C3 fragments (i.e., C3 
loading). The studies combined a  modified Ham’s test with flow cytometry. Blood from PNH 
patients was acidified in the pr esence of magnesium in order to  activate the alternative 
complement pathway and lyse the PNH erythrocytes. The cells wer e incubated in the presence 
of magnesium only (negative control), eculizumab (an anti-C5 an tibody approved to treat PNH 
and used as a positive control /  comparator) or APL-2. The surv iving erythrocytes, including 
normal and PNH RBCs, were then labeled with anti-CD59 and anti- C3d and analyzed using 
standard flow cytometry to assess protection against hemolysis.  APL-2 was as effective as 
eculizumab in protecting PNH RBC s against direct MAC-mediated h emolysis, and, unlike 
eculizumab, it was also effective in preventing massive opsoniz ation of those cells by C3 
fragments. The efficacious dose for humans has been estimated t o be between 0.5 mg/kg/d 
and 1.5 mg/kg/d. 
During safety pharmacology studies, APL-2 produced little or no  reduction in hERG current 
amplitude when tested in vitro over a concentration range of 1 μM up to 300 μM in the 
presence or absence of HSA. APL- 2 had no effects on body temper ature nor on respiratory and 
cardiovascular parameters when administered to telemeterized Cy nomolgus monkeys at doses 
of 28 or 140 mg/kg. 
4.1.2.1.2  Pharmacokinetics 
Pharmacokinetic and toxicokinetics have been performed in rabbi ts and monkeys administered 
the drug by IV or SC routes. Exc ellent bioavailability (approxi mately 85%) and t ½s in the range of 
6 to 8 days were obtained with both routes of administration in  Cynomolgus monkeys. T ½s in 
rabbits were shorter, ranging from 2 to 3 days. 
4.1.2.1.3  Toxicology 
To date, Apellis has conducted hERG channel potassium studies; in vivo assessments of 
cardiovascular and respiratory function in monkeys; pilot 7 day  studies in rabbits and monkeys; 
and 28-day repeat-dose toxicity studies in rabbits and monkeys.  A 9-month chronic dosing 
study has recently completed its in life  phase and final data from a 3-month interim necropsy 
and draft data from the 9-month necroscopy are available. A 6-m onth chronic dosing study in 
rabbits has been completed and  final data are available.  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 32 of 72 In addition, in vitro  and in vivo  assessments of genotoxicity have been performed. In all studie s, 
a group dosed with polyethylene glycol (PEG) with a molecular w eight of 40 kDa (PEG40) was 
included to assess the differences between the PEG moiety of AP L-2 and the full drug molecule, 
APL-2. 
APL-2 produced little or no reduction in hERG current amplitude  when tested in vitro over a 
concentration range of 1 μM up to 300 μM in the presence or abs ence of HSA. APL-2 had no 
effects on body temperature nor on respiratory and cardiovascul ar parameters when 
administered to telemeterized cynomolgus monkeys at doses of 28  or 140 mg/kg. 
Pharmacokinetic and toxicokinetics have been performed in rabbi ts and monkeys administered 
the drug by IV or SC routes. Excellent SC bioavailability (appr oximately 85%) was obtained in 
cynomolgus monkeys. No sex-related differences were noted in ei ther species. Serum 
concentrations were generally higher on Day 8 or Day 28 compare d to Day 1; however, at 
higher doses of APL-2 serum concentrations were not linear with  dose. Mean Cmax was 
2890 μg/mL on Day 28 and the AUC (0-24h)  was 66250 μg•hr/mL in rabbits for the 140 mg/kg/d 
animals. In monkeys, the mean Cma x was 4175 μg/mL on Day 28 and  the AUC (0-24h)  was 
94400 μg•hr/mL for the 140 mg/kg/d animals. In the 28-day studi es the estimated t½ was 
approximately 2.48 to 2.78 and 6.29 to 8.25 days in rabbits and  monkeys, respectively.  
APL-2 and PEG40 were well tolerated when administered subcutane ously to rabbits for 7 
consecutive days at doses of 20 mg/kg/d or 16 mg/kg/d (for APL- 2 and PEG40 respectively) in 
5% dextrose. There was no mortal ity noted and no effects on bod y weights, food consumption 
or injection site reactions. At termination, there were neither  macro- nor microscopic changes 
attributable to administration of APL-2 or PEG40. Not surprisin gly, APL-2 and PEG40 were mildly 
antigenic; however, the response did not affect serum concentra tions of APL-2. Serum 
concentrations of APL-2 increased with each dose during the stu dy period. 
APL-2 and PEG40 were well tolerated when administered subcutane ously to cynomolgus 
monkeys for 7 consecutive days at doses of 20 mg/kg/d or 16 mg/ kg/d (for APL-2 and PEG40 
respectively) in 5% dextrose. A dose of 16 mg/kg/d of PEG40 was  chosen as an approximation 
of the equivalent amount of PEG40 in a dose of 20 mg/kg/d of AP L-2. There was no mortality 
noted and no effects on body weights, food consumption or injec tion site reactions. At 
termination there were neither macro- nor microscopic changes a ttributable to administration 
of APL-2 or PEG40. There was no evidence of an immunologic resp onse to either molecule. 
Daily serum concentrations of APL-2 increased during the treatm ent period, with the maximum 
concentration noted on Day 6 or 8 for the two animals.  
In a 28-day GLP rabbit study with daily SC administration no dr ug-related in-life fi ndings (clinical 
signs, body weight, food consumption, ophthalmology) were obser ved at APL-2 dose levels of 7, 
28 or 140 mg/kg/d. APL-2 was well tolerated in the rabbit, with  no mortality observed. APL-2 
was shown to be weakly immunogenic at all dose levels, but PEG4 0 (112 mg/kg/d) was also 
moderately immunogenic, and thus the results observed in APL-2- dosed animals were 
attributed to the PEG40 portion of the APL-2 molecule and not t he peptide moieties. Drug-
related dose response increases in red blood cell parameters (R BCs, hematocrit, and 
hemoglobin) and reticulocyte counts were observed at the 28 and  140 mg/kg/d dose levels, and 
some, but not all parameters were resolved by the end of the 4 week Recovery Phase of the 
study. Drug-related minimal kidney tubular degeneration was obs erved in 2/12 animals dosed 
with 140 mg/kg/d, and drug-related inflammatory infiltrates at the sites of injection were 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 33 of 72 observed in the 140 mg/kg/d group . The incidence and severity o f this change appeared to be 
greater in APL-2-dosed animals than in the PEG40 group, althoug h both groups showed a 
similar inflammatory reaction. 
One histopathologic finding induced by PEG40 and not reversible  by the end of the 4 week 
Recovery Phase was macrophage vacuolation in numerous tissues ( epithelium of the choroid 
plexus in the brain, synovium of the femur, bone marrow (sternu m and femur), cervix, ovary, 
ciliary body of the eye, adrenal gland, pituitary gland, saliva ry gland, kidney, spleen, liver 
sinusoids, mandibular and/or mesenteric lymph nodes, pancreas, skin (inguinal), stomach, 
thymus and/or uterus) in both PE G40-treated animals and at all APL-2 dose levels. This finding 
is a known adaptive change to PEG and was observed in a dose-re sponse fashion. The degree 
and incidence observed at the 14 0 mg/kg/d APL-2 dose level was comparable to that in the 
PEG40 group. Thus, this adaptive finding was attributed to the PEG40 portion of the APL-2 
molecule and not the peptide moieties. PEG administration was a ssociated with decreased 
WBCs and differential lymphocyte  counts in the 28 and 140 mg/kg /d APL-2 groups and in the 
PEG40-treated group. These chang es either resolved or showed a tendency toward reversal 
during the recovery period. PEG40 also induced increases in par tial activated thromboplastin 
time and a decrease in fibrinogen levels at the 28 and 140 mg/k g/d APL-2 dose levels; both 
changes were resolved by the end  of the 4-week Recovery Phase. A no-toxic-effect dose level of 
APL-2 was concluded to be 7 mg/kg/d. 
APL-2 was well tolerated by monk eys during a 28-day GLP study f eaturing daily SC 
administration of APL-2 (0, 7, 28 or 140 mg/kg/d) or PEG40 (112  mg/kg/d). All regimens were 
without effects on in-life parame ters, which included mortality , clinical signs, body weight and 
food consumption, clinical patho logy, ophthalmology, antigenici ty evaluation, and 
electrocardiographic evaluations. No treatment-related findings  were observed in organ 
weights or gross necropsy in PEG40-treated animals or in any AP L-2 dose level. 
Histopathological changes consisting of renal tubular degenerat ion and tubule vacuolation 
were observed in animals administered either 28 or 140 mg/kg/d.  These kidney changes did not 
resolve during the 4-week Recovery Phase. Inflammatory cell inf iltrates at sites of injection 
were observed for all groups placed on study; however, high-dos e animals exhibited a greater 
severity of infiltrates which were comprised of lymphocytes, pl asma cells or granulocytes, as 
well as frequent multinucleated c ells, which appeared to be sli ghtly more pronounced 
compared to the PEG40 control group. 
PEG40 also induced macrophage vacuolation in the monkey similar  to that seen in the rabbit, in 
similar tissues (choroid plexus of the brain (epithelium), bone  marrow, adrenal gland, liver 
sinusoids, mandibular and/or mes enteric lymph nodes, ovary, pit uitary, spleen (red pulp), 
stomach, and/or urinary bladder) . An APL-2 dose-response relati onship was observed, and the 
effects in the 140 mg/kg/d group were comparable in severity an d incidence to those observed 
in the PEG40-treated animals. These changes were concluded to b e related to the PEG40 
portion of the APL-2 molecule and not the peptide moieties. A n o-toxic-effect dose level of APL-
2 was concluded to be 7 mg/kg/d. 
Neither APL-2 nor PEG40 induced genotoxicity under the conditio ns tested. Both agents were 
negative in a bacterial reverse-mutation assay (Ames test) with  and without S9 metabolic 
activation, and also negative for the induction of micronuclei in both non-activated and S9-
activated test systems in the in vitro  mammalian cell micronucleus test using TK6 cells 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 34 of 72 (proficient p53 human lymphocytes). During in vivo  assessments, APL-2 and PEG40 exhibited no 
clastogenic effect in the mouse micronucleus model. 
In summary, APL-2 had no effects on cardiovascular parameters o r hERG channel assays and 
was not genotoxic in vitro  and in vivo . In general, APL-2 was well tolerated in rabbits and 
monkeys. APL-2 was slightly to mi ldly antigenic in the rabbit, but had no observed immunologic 
effects in monkeys. A number of findings observed in the repeat ed dose toxicology studies are 
noted to be associated with high  doses of PEGylated proteins an d their clearance from the 
tissues and the body. After 28 days of administration, the prim ary finding for both APL-2 and 
PEG40 was macrophage vacuolation in various tissues and kidney tubular degeneration. 
Administration of PEGylated compounds has been associated with macrophage vacuolation in 
animals and is associated with the clearance of large molecules  from the tissues. Although 
noted in animal species, the mac rophage vacuolation has not bee n associated with either 
behavioral or clinical effects in animals nor with any serious adverse events in humans at this 
time ( Ivens, 2013 ). Furthermore, target organ toxicity in the kidneys has also b een associated 
with administration of PEG in animals ( Rudmann, 2013 ). The majority of the toxicological 
observations noted in the APL-2 groups were comparable to those  noted in the groups of 
animals receiving PEG40; thus in general, the peptide did not e xacerbate the findings 
attributable to PEG40. 
The draft toxicological data, including full histopathological assessment,  after 9 months of daily 
SC administration in the cynomologous monkey and the final toxi cological data after 6 months 
of daily SC administration in the New Zealand white rabbit, wer e comparable to those observed 
after 28 days of dosing at the s ame dose. Doses of 1, 7, and 28  mg/kg/d were investigated. 
There were no deaths, injection site reactions, ocular effects,  gross findings, or changes in 
organ weight or clinical chemistry parameters.  
Mirroring what was observed after 28 days of dosing in monkeys,  multi-tissue macrophage 
vacuolation was observed at ≥7 mg/kg/d (a non-adverse observati on) and kidney tubular 
degeneration was observed in animals at 28 mg/kg/d (an adverse reaction). Based on the draft 
data, 7 mg/kg/d is still concluded to be a NOAEL in monkeys aft er considering the toxicological 
data from the 9 month necropsy in the chronic study. Mirroring what was observed after 28 
days of dosing in rabbits, multi-tissue macrophage vacuolation was observed at ≥7 mg/kg/d (a 
non-adverse observation). Based on the draft data >28 mg/kg/d i s still concluded to be a NOAEL 
in rabbits after considering the toxicological data from the 6- month interim necropsy in the 
monkey study.  The monkey is to be  considered the pivotal speci es from a pharmacological 
standpoint (i.e. APL-2 is only active in primates) and a toxico logical observation [a kidney 
adverse event was observed at a lower dose in monkeys (28 mg/kg /d) than rabbits (140 
mg/kg/d)] that establishes the monkeys as the most sensitive sp ecies. 
In summary, a number of findings observed in the repeated dose toxicology studies are noted 
to be associated with high doses  of PEGylated proteins and thei r clearance from the tissues and 
the body. The primary adverse fi nding for both APL-2 and PEG40 was macrophage vacuolation 
in various tissues and kidney tubular degeneration. Administrat ion of PEGylated compounds 
has been associated with macropha ge vacuolation in animals and is associated with the 
clearance of large molecules from the tissues. Although noted i n animal species, the 
macrophage vacuolation has not b een associated with either beha vioral or clinical effects in 
animals nor with any serious adverse events in humans at this t ime ( Ivens, 2013 ). Furthermore, 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 35 of 72 target organ toxicity in the kid neys has also been associated w ith administration of PEG in 
animals ( Rudmann, 2013 ). Most of the toxicological observations noted in the groups o f animals 
that received APL-2 were comparable to those noted in the group s of animals that received 
PEG40; thus in general, the peptide did not exacerbate the find ings attributable to PEG40. 
Collectively there were no findings observed during any of the nonclinical studies, that would 
preclude testing chronic daily SC administration of APL-2 in hu mans. Results from the 
nonclinical APL-2 toxicology program provide good assurance of the safety of the proposed 
doses of APL-2 in humans by the SC route of administration. 
4.1.2.2  Clinical Data 
APL-2 SC injection has been tested in two healthy volunteer stu dies to assess the safety, 
tolerability, pharmacokinetics (P K) and pharmacodynamics (PD) o f APL-2. Both studies have 
been completed. The first study was a single ascending dose stu dy (Study APL-CP0713-1) and 
the second a multiple ascending dose study (Study APL-CP1014). 
APL-2 SC administration is also currently being tested in two s tudies to assess the safety and 
activity of APL-2 in patients with PNH, including this study (A PL-CP0514) and a study in patients 
who have not received prior treatment with eculizumab (APL-CP-P NH-204). 
4.1.2.2.1  Single Ascending Dose Study APL-CP0713-1  
Single SC doses of APL-2 or placebo (5% dextrose solution) have  been administered to 6 cohorts 
of healthy volunteers. The first  cohort was initiated with a se ntinel group of 2 subjects (1 active 
and 1 placebo) who were dosed 24 hours before the remaining 4 s ubjects (3 active and 
1 placebo); remaining cohorts included 5 subjects (4 active and  1 placebo). Available safety, PK 
and PD data up to Day 28 were r eviewed for each cohort before d osing of the next cohort was 
initiated. Single doses of 45, 90, 180, 360, 720 mg and 1,440 m g have been studied. 
A total of 24 subjects received single SC doses of APL-2 and 7 subjects received placebo. Single 
dose administration of APL-2 at doses up to 1,440 mg was well t olerated and no serious AEs 
were reported. The most commonly reported treatment related AEs  were headache (5/24 
subjects) and redness, itchiness, and/or bruising at the inject ion site (7/24 subjects). All 
treatment related AEs were reported as either mild or moderate in severity. There was no 
consistent onset time of the AEs in relation to the timing of t he administration and no apparent 
dose relationship with the events being reported sporadically a cross the doses studied. There 
were no treatment emergent, treatment related AEs reported in s ubjects who received the 
highest dose of 1440 mg. All AEs resolved with no sequelae. No safety signals of clinical 
relevance were observed on review of laboratory data, vital sig ns, physical examinations or 
electrocardiogram results following APL-2 administration. 
Serum APL-2 concentrations generally increased linearly with do se. APL-2 was slowly absorbed 
into the systemic circulation with median T max values between 4.5 and 6 days across the dose 
groups. After T max, serum APL-2 concentration declined in a steady mono-exponenti al manner 
with the rate of decay similar across all dose groups. Exposure  (AUC 0-inf and C max) increased 
monotonically with dose, with the power model indicating dose p roportionality. The estimated 
t½ was approximately between 8 and 10 days. PK data is presented in Table 1 below.  
 APL-2
Ascending Dose / First in Human / PNH Add-on to SOC
Apellis Pharmaceuticals, Inc. Protocol Number: APL-CP0514
V4.0 Amendment 7
Effective: 15-JUN-2017
PROT_ APL-CP0514_Amendment 7_June 15th, 2017 - CONFIDENTIAL Page 36of 72PD parameters (CH50, AP50 and complement C3 levels were measure d for all cohorts, and 
intact C3 and iC3b levels were added as additional PD parameter s for Cohort 6) were assessed 
during the study. No significant change in CH50 (classical comp lement hemolytic activity) was 
measured at any dose, however, a significant decrease in AP50 ( alternative complement 
hemolytic activity) was measured for Cohort 6. Additionally, a significant and dose-dependent 
increase in C3 levels was observed, suggesting interaction betw een APL-2 and its biological 
target, C3, as expected. Intact C3 and iC3b levels were also in creased in the only cohort where 
it was measured (Cohort 6). Seru m C3 level increase ranged from  no significant changes at the 
lowest dose (45 mg) up to an increase of approximately 100% at a dose of 1,440 mg when 
compared to levels measured in placebo subjects. Maximal levels  of C3 were measured 
approximately 8 to 11 days after  a single dose of APL-2, after which levels decreased back 
towards baseline. This increase i n C3 was not correlated with a ny increase in complement 
activity as measured by either CH50 or AP50, nor with any other  clinical observations. 
4.1.2.2.2 Multiple Ascending Dose Study APL-CP1014 
In this study, a daily SC dose of APL-2 or placebo (5% dextrose  solution) was administered to 
healthy volunteers for 28 consec utive days. This multiple dose escalation study is completed 
and final data is available. Cohorts 1 to 4 received 30 mg/d, 9 0 mg/d , 180 mg/d and 270 mg/d, 
respectively. The safety monitoring committee (SMC) reviewed sa fety and tolerability data prior 
to dose escalation throughout the study. 
In total 16 subjects (4 in each Cohort) received SC administrat ion of APL-2 for 28 days and 4 
subjects (1 in each Cohort) rece ived placebo. Multiple dose adm inistration of APL-2 at doses up 
to 270 mg/d for 28 days appeared to be safe well tolerated and no serious AEs were reported. 
The most commonly reported AEs w ere headache and URTI. Headache  was reported in 4/16 
subjects administered APL-2 and two of four subjects administer ed placebo. In the subjects 
who received APL-2, three subjec ts reported treatment-related h eadaches (one in 30 mg group, 
two in 270 mg group). In total the re were four reports of moder ate headache reported in the 
study and two of these were reported in the APL-2 270 mg group and two in the placebo group. 
Four of 16 subjects administered APL-2 reported URTI, none of w hich was considered to be 
treatment-related. Injection site reactions, reported as pain, pruritus, erythema, bruising and 
swelling, occurred in three of four subjects who received the h ighest dose (270 mg daily for 28 
days) of APL-2. The injection site reactions were mild in sever ity and sporadic in nature, i.e. not 
reported at every injection, and none were considered, by the i nvestigator to be clinically 
significant.  
 
 
 No other safety signals of 
clinical relevance were observed  on review of laboratory data, vital signs, physical examinations 
or electrocardiogram results following APL-2 administration. 
After first dose, APL-2 was slowly absorbed into the systemic c irculation with a median T max of 
24 hours across all dose groups indicating that the dose was st ill being absorbed into the 
systemic circulation at the time  of next dose. Median serum con centration increased with each 
repeat dose, with concentrations close to steady state by Day 2 2. After Day 29, serum APL-2 
concentration declined in a steady mono-exponential manner with  the rate of decay similar PPD
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 37 of 72 across all dose groups. Exposure (AUC tau and C max) increased monotonically with dose at both 
Day 1 and Day 28, indicating dose proportionality. PK data is p resented in Table 1 below.  
As with the single dose Phase I study APL-CP0713-1, a dose-depe ndent increase in C3 levels was 
observed. Additionally, a statistically significant decrease in  the alternative pathway of 
complement activity (i.e. as measured by AP50 assay) was observ ed at doses of 30, 180 and 270 
mg/d. The lowest AP50 values wer e recorded on Day 29 in the 270  mg/d group and the mean 
percentage reduction from baseline was -77%. Reductions began t o resolve on cessation of 
dosing with APL-2. C3a, C5a, int act C3 and iC3b were assessed i n the 180 and 270 mg groups 
and reductions in C3a, C5a and increase in iC3b were observed d uring the dosing period at both 
dose levels. Taken as a whole, t hese PD observations are consis tent with a conclusion that APL-
2 is interacting with complement C3 and inhibiting its activati on through the alternative 
pathway.  
4.1.2.2.3  APL-2 in eculizumab-na ïve patients with PNH 
This study is an ongoing initial  exploration of APL-2 in patien ts with PNH who have not received 
prior treatment with eculizumab. The study is comprised of two cohorts with three subjects per 
cohort, and to date, Cohort 1 has been completed and Cohort 2 i s ongoing. To date treatment 
with APL-2 270 mg/day has been w ell-tolerated for at least thre e months and has provided 
clinical benefit in subjects with PNH. Based on the emerging da ta, dosing will continue for up to 
364 days. 
4.2 Rationale 
4.2.1 Purpose of the Study 
This study will be the initial exploration of APL-2 in patients  with PNH. The assessments of the 
safety, tolerability, PK, and PD following administration of si ngle and multiples doses of APL-2 
will guide decisions to further develop the drug. 
4.2.2 Dose Selection 
APL-2 appeared well tolerated in  a panel of standard animal tox icology studies and initial 
clinical testing in healthy volunteers. Predicted C max and AUC values derived from a population-
based PK model built from available single-dose and repeated-do se clinical data. Monkey and 
human PK data were used to compare APL-2 exposures and support dose selection rather than 
the cruder method of comparing doses based on an mg/m2 basis (i.e. using a conversion factor 
of 3.1× to convert rabbit or cyn omolgus monkey mg/kg doses into  human-equivalent doses 
[HED]). 
In the nonclinical toxicology studies described in the IB, the no observed effect level (NOEL) in 
both monkeys and rabbits was det ermined to be >20 mg/kg/d in a 7 day non-GLP study (daily 
drug administration). A no observed adverse effect level (NOAEL ) between 7 mg/kg/day and 
28 mg/kg/d in both species was established during a 28-day GLP study (daily drug 
administration). Monkeys are con sidered the most relevant and p ivotal species since APL-2 is 
only pharmacologically active as  a complement inhibitor in prim ates. Additionally, PK 
parameters observed in monkeys (C max, t1/2, and AUCs) correlate better with PK data obtained 
from the clinical studies APL-CP0713-1 and APL-CP1014. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 38 of 72 The final human PK data from the studies conducted in healthy v olunteers (APL-CP0713-1 and 
APL-CP1014) were analyzed and co mpared to the PK data at the NO AEL in cynomolgus monkeys 
(see Table 1 ).  
Table 1 (updated to include final  data from the c linical trials ): Comparison of PK para meters obtained from the 
IND-enabling toxicology study and ongoing clinical trials. All values reported as arithmetic means.  
 Notes Dose 
(mg/kg) Cmax 
(μg/mL) Cmax  
% NOAEL  AUC 0-29d 
(μg•h/mL)  AUC 0-29d  
% NOAEL  AUC 0-҄҄ 
(μg•h/mL)  
Monkey NOAEL; Study 13CATX-004  7 931 -- 442,950 -- N/A 
Human 45 mg single dose; APL-CP0713-1  0.6a 7 1%   3,190 
90 mg single dose; APL-CP0713-1  1.3a 16 2%   7,670 
180 mg single dose; APL-CP0713-1  2.6a 29 3%   15,500 
360 mg single dose; APL-CP0713-1  5.1a 74 8%   30,000 
720 mg single dose; APL-CP0713-1  10.3a 139 15%   59,000 
1440 mg single dose; APL-CP0713-
1 20.6a 252 27%   98,000 
30 mg/d  x 28 days; APL-CP1014  0.43a 77 8% 28,000 b 6% 55,900b 
90 mg/d x 28 days; APL-CP1014  1.29a 259 28% 100,900 b 23%  193,200 b 
180 mg/d x 28 days; APL-CP1014  2.6a 473 51% 160,000 b 36%  320,400 b 
270 mg/d x 28 days; APL-CP1014 3.9a 670 72% 208,500 b 47%  414,000 b 
360 mg/d PREDICTED 5.14 790 85% 269,400 b 61% 510,500 b 
  a Assuming 70 kg subject. 
b AUC 0-∞was not calculated. Approxim ate values reported from  AUC 0-29 and AUC 0-84 (or AUC 0-
last) 
 
At the time of initiation of the study (when final data was not  available), a conservative 
recommended starting dose, based on predictions from PK modelli ng was selected– a dose that 
was expected to result in a C max that is 1/50th the C max observed at the NOAEL dose in monkeys 
– was 5 mg/d (0.07 mg/kg/d for a  70 kg subject). This dose was expected to result in an AUC 
exposure that was approximately 9 0 times lower than the AUC obs erved at the NOAEL dose in 
monkeys. This proposed starting dose was particularly conservat ive because the PK model used 
was based on data derived in heal thy volunteers and the PK beha vior of APL-2 might be 
substantially different in PNH patients. The initial dose provi ded PK data to confirm the validity 
of this PK model in PNH patients.  
Following review of data from ong oing studies in healthy volunt eers the doses proposed for 
Cohorts 3 and 4 were amended to 180 and 270 mg/d, respectively.  A repeated dose of 
270 mg/d of APL-2 in humans resulted in a C max of 670 Pg/mL and a total exposure (AUC 0-29d) of 
208,500 Pg•h/mL. These C max and AUC values are approxim ately 72% and 47% of those 
observed at the NOAEL dose in cynomolgus monkeys. From a pharma cological standpoint, 
180 mg/d was also the lowest dose that resulted in pharmacology  in humans (as measured by a 
decrease in AP50). As a safety consideration, only doses that h ave been previously shown to be 
well tolerated in healthy volunteers will be tested in this PNH  study.  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 39 of 72 The starting dose for Cohort 4 is 270 mg/d, with the option to increase the dose on an 
individual subject basis, up to 3 60 mg/d, which is the dose exp ected to reach approximately 
85% of the Cmax of the NOAEL obs erved in monkeys. The daily dos e will not exceed 360 mg/d 
without a protocol amendment. 
4.3 Risk/Benefit 
The safety monitoring practices employed by this protocol (i.e. , physical examination, vital 
signs, 12-lead ECG, hematology, serum chemistry, urinalysis, co agulation, injection site reaction 
monitoring, and AE questioning) are adequate to protect the sub jects’ safety. 
The approximate volume of blood planned for collection from eac h subject over the course of 
the study (see Section 0 ) has been limited to a maximum of approximately 896 mL over th e 
course of the study, in order to minimize the impact on the ove rall health of these anemic 
subjects. If the dose of APL-2 is increased above 270 mg/day, u p to three additional blood 
draws will be scheduled, requiring  an additional blood volume o f up to 45 mL (up to 687 mL in 
total). 
Systemic complement inhibition might predispose individuals to infections caused by 
encapsulated organisms, including Streptococcus pneumoniae , Neisseria meningitidis , 
and Haemophilus influenzae . Subjects will be required to provide documented evidence of 
vaccination against Neisseria meningitides types A, C, W, Y and B (administered as two separate 
vaccinations), Streptococcus pneumoniae  (Pneumococcal conjugate vaccine or Pneumococcal 
polysaccharide vaccine 23 [PCV13 or PPSV23, respectively]) and Haemophilus influenzae  Type B 
(Hib) within 2 years prior to Day 1 dosing, OR willing to recei ve appropriate vaccinations at least 
two weeks prior to dosing on Day 1 and any required booster dos es during the study (See 
Section 8.4.1  for further details). In addition to the vaccinations against these encapsulated 
organisms, prophylactic antibiotic therapy (penicillin V 500 mg  twice a day) will be prescribed to 
all subjects at the initiation of dosing (Day 1) and continue u ntil two weeks after the last dose to 
minimize potential infection risk. Body temperature and vital s igns will be monitored daily 
during the dosing portion of the study and relevant blood param eters monitored regularly 
throughout the study t o assess for signs of infection. The prin cipal investigator should be 
contacted immediately in the event of a suspected infection des pite prophylactic antibiotic 
treatment for guidance and appropriate action to be taken. 
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in 
patients on beta-lactam antibi otic (e.g. penicillin, amoxicilli n, etc.) therapy. These reactions are 
more likely to occur in individu als with a history of penicilli n hypersensitivity. Before initiating 
therapy with penicillin V, carefu l inquiry should be made conce rning previous hypersensitivity 
reactions to amoxicillin, penicillins or cephalosporins. Subjec ts with a known hypersensitivity to 
penicillin/amoxicillin may be pre scribed erythromycin 500 mg tw ice daily as an alternative 
treatment at the outset  (See Section 8.4.2  for details).  
Other frequently reported adverse effects in patients taking pe nicillin are diarrhea/loose stools, 
nausea, skin rashes, urticaria and vomiting . Patients should, therefore, be advised that these -
reactions may occur. Treatment m ay be switched to erythromycin 500mg twice daily (see 
Section 8.4.2  for details) i f there is evidence of penicillin-related tolerability issue (s uch as nausea 
and diarrhea). 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 40 of 72 As kidneys are believed to be th e key target organ for toxicity  from prolonged APL-2 high level 
exposure, renal function will be c losely monitored during this APL-2 repeated-dose clinical 
testing. 
There is a potential health bene fit for trial participants from  receipt of study drug. We propose 
to administer APL-2 to PNH patients who continue to be anemic d espite treatment with 
eculizumab. If efficacious and sa fe, APL-2 is expected to impro ve Hb levels and reduce 
transfusion dependency in these patients. At the dose level of 270 mg/d of APL-2 a significant 
decrease in complement mediated hemolytic activity was observed  in all APL-2 treated subjects 
in the healthy volunteer study. APL-2 may, therefore, reduce co mplement mediated hemolytic 
activity in PNH patients. In this context, a careful evaluation  of the risk/benefit ratio should be 
made. APL-2 at the proposed doses has been deemed safe for up t o 9 months of administration 
in preclinical and 28 days in he althy volunteer studies. Based on this data we propose to 
administer APL-2 to subjects in Cohort 4 for up to 84 days (12 weeks) in Part 2A and then for up 
to 52 weeks (Part 2B).  If subjects continue to demonstrate ben efit, APL-2 will be administered 
for up to 104 weeks (Part 2C). S ubjects will be assessed by the  Investigator every month for Part 
2A and Part 2B.  Subjects will be  assessed by the Investigator 4 weeks, 8 weeks, and then every 
12 weeks until Day 729.  The ava ilable safety, PK and PD data w ill be reviewed by the 
Investigator and Sponsor on an on going basis. If the dose of AP L-2 is increased to above 
270 mg/day, the subject will be assessed by the investigator ev ery 2 weeks (instead of every 
month) for the first 6 weeks after the dose increase. APL-2 wil l only be continued if there is 
evidence of clinical benefit to the patient, as determined by t he Investigator and the Sponsor. 
An indirect health benefit to the patients enrolled in this tri al is the free medical tests received 
at screening and during the study. 
5. STUDY OBJECTIVES AND ENDPOINTS 
5.1 Study Objectives 
The primary objectives of the study are to assess the safety, t olerability and pharmacokinetics 
of single and multiple subcutane ous (SC) doses of APL-2 in subj ects with paroxysmal nocturnal 
hemoglobinuria (PNH) who are sti ll anemic after treatment with eculizumab (Soliris®). 
An exploratory objective of the study is to assess the pharmaco dynamics (PD) of single and 
multiple SC doses of APL-2 when administered to PNH patients. S ee “Study Endpoints ” in 
Section 5.2 . 
5.2 Study Endpoints 
The primary endpoints of the stud y are the number and severity of TEAEs and PK parameters of 
APL-2 following administration of single and multiple SC doses.  
As exploratory PD endpoints, th e following markers will be stud ied: 
x Complement (e.g., CH50, AH50, and C3) hemolytic activity and le vels 
x C3 deposition on RBC cells 
x Hemoglobin 
x Reticulocytes 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 41 of 72 x Lactate dehydrogenase (LDH) 
x Bilirubin 
x Clonal distribution of PNH vs normal bone marrow derived cells 
x Th17/Treg analysis 
x Red blood cell transfusions 
6. STUDY DESIGN 
This is a Phase 1, open-label, prospective, non-randomized, sin gle and multiple ascending dose,  
study in patients with PNH. The study is planned to enroll appr oximately 15 subjects across 4 
cohorts. Cohorts 1-3 will comprise 2 subjects in each cohort. C ohort 4 will enroll sufficient 
subjects to ensure at least 6 subjects complete 28 days of dosi ng with APL-2. Subjects may 
participate in more than one cohort.  
Safety will be assessed throughout the study; serial blood samp les and urine samples will be 
collected. Blood samples will al so be collected for the PK asse ssment of APL-2. Additional 
samples for assessment of PD will also be collected. Interim PK  analyses may be performed to 
reconsider the sampling time points as the study progresses and  to guide the dose-escalation 
decision. Cumulative data will be reviewed by the Safety Monito ring Committee (SMC) on an 
regular ongoing basis and the fr equency of SMC review meetings will be described in the SMC 
charter (see Section 9.3) . 
The planned length of participation (from Screening [Visit 1] t o completion of the Exit visit) in 
the study for each subject is approximately 140 days for Cohort s 1 and 2, 115 days for Cohort 3 
and up to 785 days for Cohort 4 . 
For prior study design including single doses and waiting perio d (Cohorts 1, 2, and 3), refer to 
Version 4.0, Amendment 2, 3, and 4 of the protocol.  
Subjects in Cohort 4 will initia lly receive 270 mg SC APL-2 dai ly for 28 days. Subjects will be 
entered into the study at Visit 2 (Day 1) at a time designated by the PI and will receive daily SC 
doses of APL-2 at Visits 2 to 29. The first 4 daily SC doses of  APL-2 (Visits 2 to 5) as well as doses 
at Visits 9, 16 and 23 will be ad ministered at the clinical sit e. Subjects will remain in the clinic 
for at least 4 hours after the first dosing at Visit 2. If a su bject progresses to Part 2A, doses at 
Visits 30, 44, 58 and 72 (Days 2 9, 43, 57 and 71) will be admin istered at the clinical site, and the 
subject then progresses to Part 2B, doses at Visit 86, 114, 142 , 170, 198, 226, 254, 282, 310, and 
338 (Days 85, 113, 141, 169, 197 , 225, 253, 281, 309, and 337) will be administered at the 
clinical site.  If a subject pro gesses to Part 2C, doses at Vis its 366, 367, 368, 369, 370 and 371 
(Days 365, 421, 477, 533, 617, a nd 729) will be administered at  the clinical site.  If a subject has 
a sub-optimal clinical response du ring daily dosing with 270 mg  APL-2, the dose may be 
increased up to 360 mg/day, and doses will be administered at t he clinical site every 2 weeks 
for the first 6 weeks after comm encing the higher dose. The rem aining multiple doses will be 
administered by a trained nurse at the subject’s home, workplac e, or other location convenient 
to the subject. After completion of dosing, subjects will enter  the Part 3, and return to the 
clinical site for exit procedures  at Visit 372 Exit Visit (8 we eks after the last dose). See Study 
Flow Chart  in Section 2 . 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 42 of 72 7. SUBJECT SELECTION 
The study is planned to enroll approximately 15 subjects across  4 Cohorts. Cohorts 1-3 will 
comprise 2 subjects in each co hort. Cohort 4 will enroll suffic ient subjects to ensure at least 6 
subjects complete 28 days of dos ing. Subjects may participate i n more than one cohort. 
Additional cohorts may be enrolle d if it is deemed appropriate by the Sponsor in consultation 
with the SMC to repeat a dose le vel or to study an interim dose  level. 
7.1 Inclusion Criteria 
Subjects must fulfill all of the f ollowing inclusion criteria t o be eligible for participation in the 
study, unless otherwise specified: 
1. Male or Female 
2. At least 18 years of age 
3. Weigh >55 kg  
4. Diagnosed with PNH 
5. On treatment with eculizumab (Soliris®) for at least 3 months 
6. Hb < 10 g/dL at screening OR have received at least one transfusion within 12 months 
prior to screening 
7. Platelet count of >30,000/mm3 
8. Absolute neutrophil count >500/mm3 
9. Women of child-bearing potential (WOCBP) must have a negative p regnancy test at 
screening and must agree to use protocol defined methods of con traception for the 
duration of the study (see below) 
10. Males with female partners of child bearing potential must agre e to use protocol 
defined methods of contraception (see below) and agree to refra in from donating 
sperm for the duration of the study 
11. Willing and able to give informed consent 
7.1.1 Approved methods of contraception 
Approved methods of contraceptio n include: abstinence, oral con traceptives, intrauterine 
device, medically acceptable d ouble-barrier methods (diaphragm in combination with 
spermicidal jelly/foam, condom with spermicidal jelly/foam), im plantable or injectable 
contraceptives (like Norplant or DepoProvera) or removable birt h control device (like NuvaRing 
or Evra patches); and/or surgical sterilization (at least 6 mon ths before dosing). Subjects 
practicing abstinence and coitus  interruptus (pull out method) must agree to use an additional 
approved method of contrac eption during the study. 
7.2 Exclusion Criteria 
Subjects will be excluded from the  study if there is evidence o f any of the following criteria at 
screening or before dosing on Visit 2, as appropriate. 
1. Active bacterial infection 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 43 of 72 2. Known infection with hepatitis B, C or HIV 
3. Hereditary complement deficiency 
4. History of bone marrow transplantation 
5. Participation in any other investigational drug trial or exposu re to other investigational 
agent, device or procedure within 30 days 
6. Evidence of QTcF prolongation de fined as >450 ms for males and >470 ms for females at 
screening 
7. Creatinine clearance (CrCl) <50 mL/min (Cockcroft-Gault formula ) at screening 
8. Breast-feeding women 
9. History of meningococcal disease 
10. No vaccination against N. meningitidis  types A, C, W, Y and B  (administered as two 
separate vaccinations), Pneumoco ccal conjugate vaccine or Pneum ococcal 
polysaccharide vaccine 23 (PCV13 or PPSV23, respectively) and Haemophilus influenzae  
Type B (Hib) vaccination within 2 years prior to Day 1 (Visit 2 ) dosing. 
8. STUDY TREATMENTS 
8.1 Allocation to Treatment 
Each subject will be assigned a unique identification number up on screening. Subjects who 
complete the study screening assessments and meet all eligibili ty criteria will be scheduled to 
enter the study and dosed in the next available cohort. 
8.2 Blinding 
None:  This is an open-label study. 
8.3 Treatments Administered 
Sterile solutions of APL-2, up to  150 mg/mL, administered subcu taneously. 
8.3.1 Drug supplies 
8.3.1.1  Identity of Investigational Products 
APL-2 will be supplied either as: 1) sterile APL-2 solution in 5% dextrose at concentrations of 10, 
40, 100 or 150 mg/mL, supplied as 1-mL stoppered glass vials; 2 ) sterile APL-2 in acetate-
buffered mannitol or acetated-buffered sorbitol solution, pH 5. 0, at concentrations of up to 
60 mg/mL, supplied as 10 mL stoppered glass vials; or 3) steril e vials containing lyophilized APL-
2 supplied as stoppered glass vials, to be reconstituted to a c oncentration of 40 - 150 mg/mL 
using the 5% dextrose diluent pr ovided by the sponsor. The volu me of injection will be adjusted 
to achieve the desired dose. A separate dosing and administrati on document will be provided 
to study staff, providing details  of concentrations and volumes  for each cohort. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 44 of 72 8.3.1.2  Study Supplies 
The Sponsor will supply vials of APL-2 in 5% dextrose solution,  APL-2 acetate-buffered mannitol 
solution, APL-2 acetate-buffered  sorbitol solution or lyophiliz ed APL-2, and 5% dextrose diluent 
to the clinical site. The Sponsor will also supply needles, syr inges, infusions sets, and infusion 
pumps (e.g. Crono Super PID) as required. Drug accountability r ecords will be maintained by a 
pharmacist or other appropriately qualified designated person a t the clinical site, and will be 
made available for review by the Sponsor. 
APL-2 in 5% dextrose solution and lyophilized APL-2 should be s tored at -20°C, APL-2 acetate-
buffered mannitol and acetate-buf fered sorbitol solutions shoul d be stored at 2-8°C; and 
dextrose diluent should be stored at 15-30°C. Access to the dru g supplies should be restricted, 
and the Pharmacist or other appropriately qualified designated person will maintain drug 
accountability records. 
8.3.1.3  Accountability 
Records will be made of the receipt and dispensing of the drugs  supplied both at the clinical site 
and by the research nurse. 
Subjects will be dispensed investigational product at 4 weekly intervals.  
At the conclusion of the study, any unused investigational prod uct will be returned to the 
Sponsor or designee, or destroye d per Sponsor instructions or t he site’s SOP. If no supplies 
remain, this fact will be documented in the pharmacy product ac countability records. 
8.3.2 Planned Dose Levels 
Planned doses will be as follows: 
Cohort Planned dosing schedule (Amendment 7) 
1 25 mg on Day 1 then 5 mg/da y from Day 29 to Day 56 
2 50 mg on Day 1 then 30 mg/d ay from Day 29 to Day 56 
3 180 mg/day from Day 1 to Day 28 
4 270 mg/day (up to 360 mg/day) fr om Day 1 to Day 729* with 
optional instrasubject escalati on up to 360mg/day after Day 
28**  
*Subjects may initially receive APL-2 for 28 days (Part 1) and if there is evidence of clinical benefit they may 
continue to receive APL-2 until Day 84 (Part 2A) and if there i s ongoing evidence of clinical benefit they may 
continue to receive APL-2 until Day 364 (Part 2B). If subjects continue to have clinical benefit they may receive 
APL-2 until Day 729 (Part 2C).     
** Individual patient dose escala tion up to a dose of 360 mg/da y may occur in subjects who have a sub-optimal 
hematological response but acceptable tolerability. 
The self-administration pump can be programmed to deliver in vo lumes of one mL increments, 
and no fractions of thereof. As a result, when delivering a dos e of 270 mg, a nominal dose of up 
to 280 mg may be delivered dependent upon the concentration of the formulation (e.g. 
formulation 40 mg/mL administere d in 7mL provides a dose of 280  mg). This difference of 
approximately 4% is considered a n acceptable margin which will have minimal/no impact on 
the PK/PD or efficacy of APL-2. 
 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 45 of 72 8.3.3 Drug Administration 
A pharmacist or other appropriately qualified designated person  will dispense the vials of APL-2 
solution or vials of lyophilized APL-2 and diluent. The dispens ing and other APL-2 accountability 
records will be maintained at the clinic and made available for  review by the sponsor. If the 
dose volume is ≤3 mL, doses will be administered as 1 or 2 bolu s SC injections. If the dose 
volume is >3 mL, doses will be administered as SC infusions. Th e preferred site of 
administration is the abdomen; however, if a subject does not t olerate administration into the 
abdomen alternative sites may be selected e.g. thighs or upper arm.  
Research nurses or other appropriately qualified research perso nnel will administer bolus SC 
injections. Subjects may self-administer the SC infusions, afte r receiving appropriate training by 
a research nurse or other personnel. The injections will be adm inistered at the clinic on those 
days when a clinic visit occurs and at an off-site location con venient to the subject on all other 
days. 
8.3.4 Additional Dose Levels 
Repeat of any cohort or the addition of an interim dose level m ay be added, based on emerging 
safety, PK and PD data. Any amendments to doses will be made in  consultation with and upon 
recommendation from the SMC. The Institutional Review Board (IR B) will be immediately 
notified of this r evised approach. 
8.4 Concomitant Medications 
8.4.1 Vaccinations 
Subjects will be required to provide documented evidence of hav ing received the following 
vaccines within 2 years prior to Day 1 dosing. 
x Neisseria meningitides types A, C, W, Y: Menactra®, Menomune® or Menveo®  
x Neisseria meningitides type B: Bexsero® or Trumenba®  
x Streptococcus pneumoniae: Prevnar 13®(PCV13) or Pneumovax® (PPSV23)  
x Haemophilus influenzae  type B: PedvaxHIB®, ActHIB® or Hiberix®  
If subjects are not able to prov ide documented evidence of havi ng received the vaccinations 
above, they will receive the vaccinations following the CDC’s r ecommendations for vaccination 
in patients with immunocompromissing conditions as described be low ( CDC, 2016 ). 
x Neisseria meningitides types A, C, W, Y: Menactra®, Menomune® or Menveo®. First dose 
at least two weeks prior to dosi ng on Day 1 with a booster afte r 2 months.  
x Neisseria meningitides type B: Bexsero® or Trumenba®. First dose at least two weeks 
prior to dosing on Day 1 with a booster after 2 months.  
x Streptococcus pneumoniae: Prevnar 13®(PCV13) at least two weeks prior to dosing on 
Day 1 and Pneumovax® (PPSV23) after 2 months.  
x Haemophilus influenzae  type B: PedvaxHIB®, ActHIB® or Hiberix® at least two weeks 
prior to dosing on Day 1. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 46 of 72 8.4.2 Prophylactic antibiotics 
Prophylactic antibiotic therapy will be prescribed to all subje cts to minimize potential infection 
risk. Prophylactic antibiotics will be initiated at Visit 2 bef ore initiation of APL-2 dosing and 
continue until 2 weeks after the last dose of study medication.  
8.4.2.1  Primary prophylactic antibiotic 
x Penicillin V 500 mg twice daily 
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in 
patients on beta-lactam antibi otic (e.g. penicillin, amoxicilli n, etc.) therapy. These reactions are 
more likely to occur in individu als with a history of penicilli n hypersensitivity. Before initiating 
therapy with penicillin V, careful inquiry should be made conce rning previous hypersensitivity 
reactions to amoxicillin, penicillins or cephalosporins. If sub jects have a known hypersensitivity 
to penicillin/amoxicillin they may be prescribed an alternative  antibiotic at the outset. 
Other frequently reported adverse effects in patients taking pe nicillin are diarrhea/loose stools, 
nausea, skin rashes and urticaria, and vomiting . Patients should, therefore, be advised that 
these reactions may occur. 
8.4.2.2  Alternative prophylactic antibiotics 
x Erythromycin 500 mg twice daily 
Erythromycin 500 mg twice daily may be considered as a suitable  alternative in subjects who 
are unable to tolerate penicillin. 
Treatment should be switched to another alternative antibiotic if there is evidence of penicillin 
or erythromycin-related tolerab ility issue (such as nausea and diarrhea). The PI will discuss and 
agree to a suitable alternative w ith the sponsor’s medical moni tor. The agreement will be noted 
in the subject’s medical records. 
8.4.2.3  Rescue antibiotics 
Body temperature and vital signs will be monitored daily during  the dosing portion of the study 
and relevant blood parameters mo nitored regularly throughout th e study to assess for signs of 
infection. The principal investigator should be contacted immed iately in the event of a 
suspected infection despite prophylactic antibiotic treatment f or guidance and appropriate 
action to be taken. Action to be  taken may include administrati on of a broad spectrum 
antibiotic to cover possible re sistant organisms such as resist ant pneumococcus (e.g. 
levofloxacin/augmentin). 
9. STUDY PROCEDURES 
Please see the Study Flow Chart in Section 2 for a summary of the schedule of study 
participation and procedures. 
9.1 Screening (Visit 1) 
Screening will begin within 30 days prior to dosing to confirm that subjects meet the subject 
selection criteria for the study . Informed consent will be obta ined at screening (see Section 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 47 of 72 13.3.3 ). Subjects will have to meet all eligibility criteria before b eing enrolled into the study (see 
Section 7 ). 
The following will be recorded at screening: medical history an d demographic data, including, 
sex, age, race, body wei ght (kg), height (cm). 
Screening procedures are listed in the Study Flow Chart in Section 2 . 
9.2 Treatment Period (Visits 2 to 36) 
For prior study design including dosing schedules for Cohort 1,  2, and 3, refer to Version 4.0, 
Amendments 2, 3, and 4 of the protocol. 
9.2.1 Dosing Period (Visits 2 to 729) 
Subjects will receive daily SC doses of APL-2 in the mornings o f Visits 2 to 29. Following review 
of available safety, PK and PD data by the Investigator and Spo nsor subjects demonstrating 
clinical benefit from the treatment may progress to Part 2A of the study and continue to receive 
daily doses of APL 2 until Visit 85 (Day 84) , then subjects co ntinuing to demonstrate clinical 
benefit from the treatment may progress to Part 2B of the study  and continue to receive daily 
doses of APL 2 until Visit 365 ( Day 364). Subjects continuing t o demonstrate clinical benefit may 
progress to Part 2C of the study and continue to receive daily doses of APL-2 until Visit 371 (Day 
729). APL-2 will be administered at the site by study personnel  or at the subject’s home, 
workplace, or other location convenient to the subject by a tra ined research nurse. Subjects 
may self-administer the SC infus ions, after receiving appropria te training by a research nurse or 
other personnel. 
9.2.1.1  Clinical Site Administration (Part 1 Visits 2-5, 9, 16, & 23; P art 2A Visits 30, 44, 
58, & 72, and Part 2B Visits 86, 114, 142, 170, 198, 226, 254, 282, 310, 338; 
Part 2C Visits 366, 367,  368, 369, 370 and 371) 
Subjects will receive a daily SC dose of APL-2 starting on Visi t 2. See Section 8.3.2 . 
The first 4 daily SC doses of APL -2 (Visit 2 to 5) as well as d oses on Visits 9, 16, 23, 30, 44, 58 and 
72 will be administered at the cl inical site. Subjects will rem ain in the clinic at least 4 hours after 
dosing at Visit 2 only. 
Blood samples for PK/PD will be t aken at the following time poi nts during Visit 2 to Visit 86 of 
the study: 
x PK + PD: Pre-dose at Visit 2 
x PK: 4 hours post-dose at Visit 2 
x PK only: Pre-dose at Visits 3, 4 and 5 
x PK + PD: Pre-dose at Visits 9,  16, 23, 30, 44, 58 and 72. 
Blood samples for PK/PD will be t hen be taken pre-dose at every  subsequent scheduled clinic 
visit up to and including the Exit Visit. 
 
Additional procedures for each visit are listed in the Study Flow Chart  in Section 2 . 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 48 of 72 9.2.1.2  Multiple-Dose Outpatient Administration (Part 1 Visits 6-8, 10- 15, 17-22 and 
24-29; Part 2A Visits 31-43, 45-57, 59-71, & 73-85, Part 2B Vis its 87-113, 115-
141, 143-169, 171-197, 199-225, 227-253, 255-281, 283-309, 311- 337, and 
339-365, Part 2C Visits 366, 367, 368, 369, 370 and 371) 
From Visit 6 to Visit 371, with the exception of doses administ ered at the clinical site as 
specified above, daily doses of APL-2 will be administered by a  trained research nurse, 
caregiver, or self-administered. These daily doses of APL-2 may  be administered at the subject’s 
home, workplace, or other locati on convenient to the subject. 
If a trained research nurse completes APL-2 administration, saf ety, tolerability and concomitant 
medication will be monitored. If the subject (or caregiver) sel f-administers the SC infusions, 
after receiving appropriate training by a research nurse or oth er personnel, adverse events and 
concomitant medications will be reported to the clinic site. 
9.2.2  Exit Visit (Visit 372)  
All subjects will be asked to retu rn to the clinic al site for a n Exit Visit 8 weeks following the last 
administration of APL-2. For any  subject enrolled in the study,  study participation will be 
concluded following the Exit visit evaluations (Visit 372) appr oximately 8 weeks after the last 
dose of APL-2 or at early termin ation. Should any subject withd raw or be withdrawn from the 
study, the Exit visit evaluations should be performed including  the collection of blood samples 
for PK and/or PD assessments, as well as a post-dose antigenici ty sample if not yet collected. 
Blood samples for PK/PD will be taken at Exit Visit. The Exit v isit procedures are listed in the 
Study Flow Chart  in Section 2 . 
9.2.3 Unscheduled Follow-up Visits 
The safety and PK sampling may be extended or modified with add itional follow-up visits. 
All subjects will be asked to retu rn to the clinic al site for a dditional follow-up visits if considered 
necessary by the PI, the sponsor or the SMC or if PK/PD samplin g schedule is modified or 
extended based on interim results. 
Unscheduled follow-up visits may  include any of the procedures listed in the Study Flow Chart  
in Section 2 . 
9.2.4 Scheduled End of Study 
The end of the study is scheduled after completion of the Exit visit evaluations in the 4 cohorts. 
This may change in the event that the study is terminated early  if dose-limiting clinical safety 
endpoints have been reached to preclude further increases of do se, additional cohorts are 
enrolled, additional time is required to review safety data, ex tended safety and PK sampling is 
added for a cohort (e.g., extende d beyond Visit 372), or a deci sion is made to complete an 
unscheduled analysis between cohorts. 
9.3 Dose Escalation and Periodic Safety Review  
Initiation of the next dose level (i.e. next cohort) will occur  as follows: 
For Cohorts 1 and 2, subjects will receive a single SC dose of APL-2 on Day 1. At least twenty-
eight days after they receive th e single injection, subjects wi ll enter the multiple-dose period 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 49 of 72 and will receive SC APL-2 daily for 28 days at the correspondin g multiple dose for their cohort. 
After both subjects in the preceding cohort have completed the single-dose 28-day waiting 
period, the next cohort will be started at the next planned sin gle dose level. 
For Cohort 3, subjects will receive SC APL-2 daily for 28 days at the corresponding multiple dose 
for their cohort. After both subj ects in the preceding cohort h ave completed the 28-day dosing 
period, the next cohort will be started at the next planned dos e level. 
 
For Cohort 4, the treatment period will consist of three parts as outlined in the diagram below. 
In Part 1, subjects will receive APL-2 for 28 days. At Visit 30  on Day 29, subjects concluded to 
benefit from the treatment (as determined by the Investigator a nd Sponsor after reviewing the 
available data) will automatically  enter into Part 2A and conti nue treatment for an additional 56 
days (Days 29 to 84). At Visit 86 on Day 85, subjects continuin g to benefit from the treatment 
(as determined by the Investigator and Sponsor after reviewing the available data) will 
automatically enter into Part 2B and continue treatment for an additional 309 days (Days 85 to 
364).  
 
 
9.3.1 Safety Monitoring Committee 
An external, independent Safety Monitoring Committee (SMC) will  review cumulative 
safety/tolerability data (e.g., physical examinations, electroc ardiograms [ECGs], vital signs, 
clinical laboratory tests, and adverse events [AEs]) and PK dat a including predicted exposures 
for subsequent doses based on emerging PK data and will have th e responsibility to conduct a 
thorough safety assessment at regular (monthly) intervals durin g the dose escalation phase of 
the study. A key responsibility of this committee will be to ma ke a recommendation whether to 
continue, modify or stop dose escalation (or the study) based u pon an evaluation of emerging 
safety data, in particular Advers e Events of Special Interest a s outlined in Section 11.5 . The SMC 

 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 50 of 72 will comprise at least of a Hemat ologist with PNH experience an d an Infectious Disease 
Specialist. The SMC will meet reg ularly as defined in the SMC c harter, commencing before 
initiation of Cohort 2. Dose escalations and continuation beyon d 28 days (Cohort 4) will not 
always coincide with SMC meeting s. Additional regular or ad-hoc  safety reviews will be 
scheduled as recommended by the committee or requested by the S ponsor. 
The remit, roles, and responsibilities of the SMC will be speci fied in a separate SMC charter. 
9.4 Removal of Subjects from the Study 
Subject participation in this tr ial may be discontinued for any  of the following reasons: 
1. Occurrence of any medical condition or circumstance that expose s the subject to 
substantial risk and/or does not allow the subject to adhere to  the requirements of the 
protocol. 
2. Any SAE, clinically significant AE , severe laboratory abnormali ty, intercurrent illness, or 
other medical condition that indicates to the PI that continued  participation is not in the 
best interest of the subject. 
3. Subject's decision to withdraw. 
4. Subject failure to comply with protocol requirements or study r elated procedures. 
5. Termination of the study by the Sponsor, FDA, or other regulato ry authorities. 
The clinical report will include reason(s) for subject withdraw als as well as details relevant to 
the subject withdrawal. If a subject is withdrawn from the tria l prior to study completion, the 
subject will undergo all procedures scheduled for study complet ion (Exit visit) as the situation 
allows. Any subject withdrawn due  to an AE (whether serious or non-serious) or clinically 
significant abnormal laboratory test values will be evaluated b y the PI or a monitoring physician 
and will be treated and/or followed until the symptoms or value s return to normal or 
acceptable levels, as judged by the PI. 
Subjects withdrawn will not be replaced. 
10. ASSESSMENTS 
10.1 Safety Assessments 
This study primarily assesses the safety and tolerability of AP L-2. Safety will be determined by 
evaluating physical examinations, vital signs, ECGs, clinical l aboratory parameters, injection site 
reactions and AEs as outlined in the Study Flow Chart  in Section 2 .  
If deemed necessary, additional safety measurements will be per formed at the discretion of the 
PI. 
10.1.1  Body Height and Weight 
Body height (centimeters) and body weight (kilograms) will be m easured at screening as part of 
the physical examination.  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 51 of 72 10.1.2  Physical Examination 
All physical examinations include, at a minimum, assessment of the following: general, head, 
ears, eyes, nose, throat, dentition, thyroid (endocrine), heart , chest, lungs, abdomen, skin, 
extremities, back/neck, muscul oskeletal, and lymph nodes. 
A licensed physician employed a t the study site will examine ea ch subject as outlined in the 
Study Flow Chart  in Section 2 . 
Medical history will be recorded at screening.  A symptom-driven physical examin ation may be performed at vario us unscheduled time points 
if deemed necessary by the PI. 
10.1.3  Vital Signs 
Single measurements of body temperature, respiratory rate, bloo d pressure, and heart rate will 
be measured as outlined in the Study Flow Chart in Section 2 . 
Vital signs may be taken at any other times, if deemed necessar y. Blood pressure and heart rate 
measurements will be performed wit h subjects in a seated positi on after resting for 5 minutes, 
except when they are supine or semi-reclined because of study p rocedures and/or AEs (e.g., 
nausea, dizziness) or if deemed necessary by the PI. 
Vital signs will be measured before venipuncture and ECG. On dosing days, vital signs will be measured pre- and post-dose . Vital signs will be measured 
within 2 hours prior to dosing for the pre-dose time point. Pos t-dose vital signs will be 
performed within approximately 30 minutes after dosing. 
10.1.4  Electrocardiogram Monitoring 
Single 12-lead ECGs will be measured at the time points outline d in the Study Flow Chart  in 
Section 2 .  
On dosing days, 12-lead ECGs will be performed post-dose within  approximately 30 minutes 
after completion of dosing.  
ECG time points will be guided by PK data and will be collected  around the estimated T
max. The 
time points may be changed depending on PK information obtained  from previous cohorts. 
ECGs will be taken following resti ng in the supine position for  10 minutes in a quiet 
environment. 
ECGs will be interpreted, signed and dated by the PI. The ECGs will be classified as normal, 
having a not clinically significant (NCS) abnormality, or havin g a clinically significant (CS) 
abnormality. In addition, ECG pa rameters of ventricular rate, P Q or PR interval, QRS duration, 
and QT interval (corrected using both Bazett’s and Fredericia’s  method and uncorrected) will be 
noted on the CRF. All CS fi ndings will be recorded as AEs. 
10.1.5  Functional Assessment of Chronic  Illness Therapy (FACIT) Fatigu e Scale 
The FACIT Fatigue Scale is a 13 item Likert scaled instrument w hich is self-administered by the 
subjects during clinic visits on Days 1 and 15 in Part 1; Days 29, 43, and 71 in Part 2A; Days 86, 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 52 of 72 142, 198, 253, and 309 in Part 2B; Days 533 and 729 in Part 2C and during the Exit Visit on Day 
785 (see Appendix 1  for details). 
10.1.6  Clinical Laboratory Tests 
All tests listed below will be performed as outlined in the Study Flow Chart  in Section 2 . In 
addition, laboratory safety tests may be performed at various u nscheduled time points, if 
deemed necessary by the PI. The clinical laboratory tests inclu de (but are not limited to) the 
following: 
10.1.6.1  Hematology 
x Hemoglobin 
x Hematocrit 
x Red blood cell (RBC) count x Platelet count  
x White blood cell (WBC) count with 
differential 
10.1.6.2  Coagulation 
x Prothrombin time (PT) 
x Fibrinogen x Activated partial thromboplastin time (aPTT) 
x D-Dimer 
10.1.6.3  Serum Chemistry 
x BUN 
x Creatinine 
x Estimated creatinine clearance 
(using Cockcroft-Gault formula) –screening only 
x
 Bilirubin (total and direct) 
x Uric acid 
x Albumin 
x Alkaline phosphatase (ALP) 
x Lactate dehydrogenase (LDH) x Creatine kinase  
x Aspartate aminotransferase (AST) 
x Alanine aminotransferase (ALT) 
x Gamma glutamyl transpeptidase (GGT) 
x Glucose  
x Sodium 
x Potassium 
x Chloride 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 53 of 72 10.1.6.4  Urinalysis 
x pH 
x Specific gravity 
x Protein 
x Glucose 
x Ketones x Bilirubin 
x Blood 
x Nitrite 
x Urobilinogen 
x Leukocyte esterase 
If an abnormality is noted for protein, blood, nitrite and/or l eukocyte esterase, a 
microscopic examination will be performed.  
10.1.6.5  Serology 
x HIV 
x HBsAg x HCV 
10.1.6.6  Human Chorionic Gonadotropin (Serum Pregnancy Test) and Follicu le-
Stimulating Hormone 
Serum Pregnancy Test will be performed for females only. FSH wi ll be performed for 
postmenopausal females at screening only. 
10.1.7  Injection Site Assessment 
An assessment of the APL-2 injec tion site will be performed at each dosing day, within 30 min 
after completion of study drug ad ministration. The assessment w ill be performed by a physician 
or other licensed health care provider (i.e. study nurse) as de legated by the PI. The injection site 
and the surrounding area will be inspected for redness, swellin g, or induration; and the subject 
will be queried about the presenc e of pain and/or tenderness (S ee Appendix 2 for details). The 
date, time, and outcome of the injection site assessment will b e recorded on the source 
documents and CRFs. Any abnorm al findings will be reported as a dverse events according to 
protocol Section 11 . 
10.2 Pharmacokinetic Assessments 
10.2.1  Blood Sampling and Processing 
Blood samples for PK assessment of APL-2 will be collected via direct venipuncture at the time 
points delineated in the Study Flow Chart  in Section 2 . 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 54 of 72 The allowable post-dose deviation window is as follows: 
Sample time  Allowed deviation  
Sampling ≤ 72 hours after first multiple dosing ±30 minutes  
Sampling >72 hours  ±10%   
PK samples during multiple dosing will be collected pre-dose. 
Preliminary PK analysis may be performed to reconsider sampling  time points as the study 
progresses or to guide the dose escalation decision. 
Instructions for collection, handling, processing, storage, and  shipping of samples will be 
provided in a separate sample handling manual prior to study in itiation. 
10.2.2  Analytical Method 
Serum sample analysis will be performed using GLP-compliant val idated procedures and 
methods. The methods used and the results obtained will be incl uded in the final report as an 
appendix. 
10.3 Pharmacodynamic Assessments 
Blood samples will be collected v ia direct venipuncture at the time points delineated in the 
Study Flow Chart  in Section 2 for PD assessment of complement activation through the classica l 
(e.g., CH50) and alternative (e. g., AH50) pathways, PNH clone d istribution, C3 deposition on 
RBCs and Th17/Treg profile. Bloo d samples will also be collecte d to measure C3 levels. Other 
relevant PD markers may also be assessed. 
Preliminary PD analysis may be performed to reconsider sampling  time points as the study 
progresses or to guide the dose escalation decision. 
Instructions for collection, handling, processing, storage, and  shipping of samples will be 
provided in a separate sample handling manual prior to study in itiation. 
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 55 of 72 10.4 Blood Volume for Study Assessments 
Table 2: Blood Volume during Study (up to Visit 372) 
Assay Number 
of Time 
Points *  Approximate 
Volume per Time 
Point ** (mL) Approximate 
Sample Volume 
Over Course of 
Study (mL) 
Pharmacokinetics 32 2 64 
 
Anti-APL-2 Ab assay 20 2 40 
Hematology 29 3 87 
Chemistry (Incl. screen serology and pregnancy) 29 6 174 
Coagulation profile 26 4.5 117 
Complement profile (C3, CH50 and AH50)*** 28 4 112 
Flow cytometry for PNH and C3 deposition 28 2 56 
Th17/Treg Analysis 10 19 190 
Free hemoglobin  28 2 56 
Total Blood Volume for Study  896 mL 
* If the dose of APL-2 is increased above 270 mg/day, an additi onal 15 mL blood will be collected at up to three 
time-points, and the total blood volume for the study will incr ease to a maximum of 941 mL. 
* Represents the largest collection volume planned over the dur ation of the study (smaller tubes will be used 
whenever possible). 
** AH50 and AP50 both measure the hemolytic activity of alterna tive pathway of compleme nt in blood samples. 
AH50 is reported in this study a nd AP50 has been used in other studies noted in this protocol. 
10.5 Pregnancy tests 
For WOCBP, a serum pregnancy test will be performed at screenin g, and subjects with a 
positive test will be excluded from the study. A follow up urin e pregnancy test will be 
performed at Visit 2 pre-dose (a negative urine pregnancy test must be received before dosing 
with study drug). A urine pregna ncy test will also be performed  at each site visit. A final urine 
pregnancy test will be performed a t the final Exit visit (Visit  372 or early termination). Male 
subjects will be counseled to avoi d donating sperm after dosing  at Visit 2 until the final Exit 
visit. 
11. ADVERSE EVENTS 
11.1 Definitions 
An adverse event (AE) is any unto ward medical occurrence associ ated with the use of a drug in 
humans, whether or not considered drug related. An AE can there fore be any unfavorable and 
unintended sign, including a clinically significant abnormal la boratory finding, symptom, or 
disease temporally associated wit h the use of a study drug, whe ther or not considered related 
to the study drug.  
Adverse events include  the onset of new illness and the exacerb ation of pre-existing conditions. 
Any medical condition that is pre sent at the time that the subj ect is screened should be 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 56 of 72 recorded on the medical history eCRF and not reported as an AE.  However, if that condition 
deteriorates or severity changes  at any time during the study, it should be recorded as an AE. 
Any AEs that occur prior to dosing at Visit 2 will be categoriz ed as pre-treatment events. 
Treatment-emergent adverse events (TEAEs) will be defined as th ose AEs that occur after 
dosing at Visit 2 and up to 30 days after the last dose of stud y medication.  
A suspected adverse reaction mea ns any AE for which there is a reasonable possibility that the 
drug caused the AE. Reasonable possibility means there is evide nce to suggest a causal 
relationship between the drug and the AE.  
11.2 Recording Adverse Events 
Subjects will be monitored for adverse events throughout the st udy. Adverse events may be 
volunteered spontaneously by the study subject, or discovered b y the study staff during 
physical examinations, or by asking open, non-leading questions  (e.g. “How have you been 
feeling since the last clinic vis it?”). Subjects will be instru cted to inform the investigator and/or 
study staff of any AEs that may occur at any time during the st udy. 
All AEs occurring from screening  through the final Exit visit w ill be recorded in detail in the 
source documents and documented on the appropriate AE or SAE eC RF. The nature of the AE, 
date (and time, if known) of AE onset, duration, severity, and action taken will be documented, 
together with the investigator ’s assessment of the seriousness of the AE and relationship to 
study drug. All AEs should be recorded in the study subject’s o wn words (verbatim), unless in 
the opinion of the Investigator, the AE constitutes a recognize d condition, disease, or 
syndrome. In that case, the condition, disease or syndrome shou ld be named rather than the 
individual symptoms. The AEs will be coded using the current Me dical Dictionary for Regulatory 
Activities (MedDRA).  
Outcome will be recorded as:  
x Ongoing  
x Resolved 
x Resolved with sequela  
x Death or  
x Unknown 
11.3 Assessment of Adverse Events 
Each AE will be assessed by the Investigator or physician desig nee with regard to the categories 
discussed in the sections below. 
11.3.1  Intensity 
The Investigator will determine the severity of each AE. Locali zed injection site reactions will be 
closely monitored and will be graded according to the FDA Guida nce for Industry: Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrol led in Preventive Vaccine Trials 
(FDA, 2007 ). See Appendix 2  for details. 
x All other AEs will be graded according to the Common Terminolog y Criteria for Adverse 
Events (CTCAE) version 4.03. The following definitions for rati ng severity will be used: 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 57 of 72 Grade 1  Mild; asymptomatic or mild sym ptoms; clinical or diagnostic 
observations only; intervention not indicated.  
Grade 2  Moderate; minimal, local or nonin vasive intervention indicated;  
limiting age-appropriate instrumental Activities of Daily Living 
(ADL)*.  
Grade 3  Severe or medically significant but not immediately life -
threatening; hospitalization or prolongation of hospitalization  
indicated; disabling; limiting self -care ADL**. 
Note : An exper ience may be severe but may not be serious, e.g., 
severe headache.  
Grade 4  Life-threatening consequences; urgent intervention indicated. 
Grade 5  Death related to AE 
A semi-colon indicates ‘or’ withi n the description of the grade . 
*Instrumental ADL refer to preparing meals, shopping for grocer ies or clothes, using the telephone, managing money, etc. 
**Self-care ADL refer to bathing, dressing and undressing, feed ing self, using the toilet, taking medications, and not bedridd en. 
When changes in intensity of an AE occur more frequently than o nce a day, the maximum 
intensity for the event should be noted for that day. Any chang e in severity of signs and/or 
symptoms over a number of days w ill be captured and recorded as  a new AE, with the amended 
severity grade, and the date and  time (if known) of the change.  
11.3.2  Causality 
The relationship of an AE to the study drug will be assessed us ing the following criteria: 
Unrelated  x Does not follow a reasonable temporal sequence from the 
administration of study drug  
x The event or laboratory test abnormality is clearly due to extraneous 
causes (disease, other drugs, environment, etc.) 
Unlikely  x Does not follow a known pattern of response to study drug 
x Does not follow a reasonable temporal sequence from the 
administration of study drug 
x Disease or other drugs provides plausible explanation 
x It does not reappear or worsen when study drug is re-administer ed 
Possibly  x Follows a known pattern of response to study drug 
x Time sequence from administration of the study drug is reasonab le 
x Could also be explained by disease or other drugs 
Probably  x Follows a known pattern of response to study drug 
x Time sequence from administration of the study drug is reasonab le  
x Response to withdrawal clinically reasonable 
x Cannot be reasonably explained by the known characteristics of the 
participants clinical state, environmental factors, or other th erapies 
administered to the subject 
 APL-2
Ascending Dose / First in Human / PNH Add-on to SOC
Apellis Pharmaceuticals, Inc. Protocol Number: APL-CP0514
V4.0 Amendment 7
Effective: 15-JUN-2017
PROT_ APL-CP0514_Amendment 7_June 15th, 2017 - CONFIDENTIAL Page 58of 7211.3.3 Serious Adverse Event 
A serious adverse event (SAE) is  defined as any untoward medica l occurrence that at any dose: 
xResults in death; 
xIs  life- thr eate ning : this  means  tha t the  s u bj ec t  w as  at ris k  o f  death at the time of the 
event; it does not mean that the event might have caused death had it occurred in a 
more severe form; 
xRequired hospitalization or prolongation of existing hospitaliz ation; 
xResults in persistent or signifi cant incapacity or substantial disruption of the ability to 
conduct normal life functions; 
xIs a congenital anomaly or birth defect. 
Important medical events that may not result in death, be life- threatening, or require 
hospitalization may be considered serious when, based upon appr opriate medical judgment, 
they may jeopardize the patient or subject and may require medi cal or surgical intervention to 
prevent one of the outcomes listed in the above definition. Exa mples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient  hospitalization, or the 
development of drug dependency or drug abuse. 
Medical and scientific judgment should be exercised in deciding  if an AE is serious and if 
expedited reporting is appropriate. 
11.4 Reporting Serious Adverse Event 
The reporting period for adverse events begins as soon as the s ubject’s written consent to 
participate in the study has been obtained, and continues throu gh the final Exit visit. The 
Investigator is responsible for reporting all SAEs to the Safet y Monitor, whether or not the 
event is considered related to the study drug.  
If an SAE occurs, the Investigator should complete and sign the  SAE Report Form, and fax it to 
the Safety Monitor at the number listed below within 24 hours o f becoming aware of the event:  
Telephone No.:   Telephone No.:   
Toll Free No.:     
Facsimile No.:    
The initial SAE Report should include, at a minimum, the follow ing information: 
xStudy number 
xSubject ID number 
xGender 
xDate of birth 
xName of PI and full clinical site address 
xDetails of SAE 
xCriterion for classification as “serious” 
xStudy drug name and treatment start date 
xDate of SAE onset PPD
PPD
PPD
PPD
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 59 of 72 x Causality assessment (if sufficient information is available to  make this determination) 
The Safety Monitor will request clarification of omitted or dis crepant information from the 
initial report. The Investigator or designee is responsible for  faxing the requested information 
to the Safety Monitor within 24 hours of the request.  
Initial reports of SAEs must be followed later with detailed de scriptions, including clear copies 
of supporting documents as necessary (e.g. hospital discharge s ummary, laboratory reports, 
autopsy reports, etc.), with the subject’s personal identifiers  removed. If a new SAE Report 
Form is faxed, the Investigator must sign and date the form.  
The Investigator must report all SAEs to the IRB/IEC according to the institutional IRB/IEC policy.  
11.5 Adverse Events of Special Interest 
An adverse event of special inter est (AESI) is one of scientifi c and medical concern specific to 
the Sponsor’s product or program where ongoing monitoring and r apid communication by the 
PI to the Sponsor may be appropriate. These adverse events may be serious or non-serious. 
Applicable adverse events may req uire further investigation in order to characterize and 
understand them, and depending up on the nature of the event, ra pid communication by the 
Sponsor to other parties may also be required. These adverse ev ents of special interest must be 
reported promptly to the sponsor . The adverse events of special  interest include the following: 
x Local or systemic infection of any origin 
x Clinically significant decr ease in kidney function 
x Injection site reactions 
x Thromboembolic events  
x Infusion pump related events 
If an AESI occurs in a study subject, the study subject will be  followed for resolution of the 
adverse event. A decision will be  made by the Sponsor concernin g further exposure to the 
study treatment and further participation in the study. 
 
11.6 Unexpected Adverse Events or Unexpected Suspected Adverse React ions 
An AE or suspected adverse reaction is considered “unexpected” if it is not listed in the 
Investigator’s Brochure (IB) or is not listed at the specificit y or severity that has been observed; 
or is not consistent with the risk information described in the  general investigational plan or 
elsewhere in the current application. For example, under this d efinition, hepatic necrosis would 
be unexpected (by virtue of increased severity) if the IB refer red only to elevated hepatic 
enzymes or hepatitis.  
The Sponsor will be responsible for reporting any serious and u nexpected adverse events to the 
applicable regulatory agencies as required.  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 60 of 72 11.7 Treatment and Follow up of Adverse Events 
AEs (whether serious or non-serious), including clinically sign ificant abnormal laboratory test 
values, will be evaluated by the Investigator and treated and/o r followed until the symptoms or 
value(s) return to baseline or a re clinically stable. Treatment  of AEs will be performed by 
appropriately trained medical pe rsonnel, either at the clinical  site or at a nearby hospital. When 
appropriate, medical tests and/or examinations will be performe d to document resolution of 
the event(s).  
AEs continuing after completion of the study will be followed u p by telephone or with visits per 
the discretion of the Investigato r. If possible, the outcome of  any AE that caused 
discontinuation from the study or was present at the end of the  study should be reported, 
particularly if the AE was considered by the PI to be related t o the study drug.  
11.8 Pregnancy  
Although pregnancy is not considered an AE, the outcome of a pr egnancy, if there is a 
spontaneous abortion, congenital anomaly or other adverse fetal  outcome, may be an SAE. All 
SAEs are to be reported to the study sponsor on the SAE Reporti ng Form. 
Women of child-bearing potential (WOCBP) and males with female partners of child-bearing 
potential will be instructed to p ractice an acceptable method o f birth control (as defined in 
Section 7.1.1 ) for the duration of the study. 
If a female subject or partner of a male subject becomes pregna nt during the study, the 
Investigator should report the pregnancy to the Safety Monitor within 24 hours of being 
notified. The subject or partner  should be followed by the Inve stigator until completion of the 
pregnancy. At the completion of the pregnancy, the Investigator  will document and report the 
outcome. If the outcome of the p regnancy meets the criteria for  classification as an SAE (i.e. 
postpartum complication, stillbirth, neonatal death, or congeni tal anomaly) the Investigator 
should follow the procedures for reporting an SAE ( Section 11.4 ).  
12. STATISTICS  
12.1 Sample Size Justification 
The sample size was chosen to be sufficient to address safety, tolerability and PK analyses. All 
collected data will be enumerate d in listings, summary data wil l be tabulated, and no formal 
statistical testing is planned for the study data.  
12.2 Statistical Analysis Methodology  
A formal Statistical Analysis Plan (SAP) will be developed and finalized prior to locking the data. 
The full details of the data pre sentation and analysis will be provided therein. Any deviations 
from the final analysis plan will be discussed in the final stu dy report. Additional statistical 
analyses other than those described in this section may be perf ormed if deemed appropriate 
and included in the SAP. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 61 of 72 12.2.1  Study Analysis Datasets 
The intent-to-treat (ITT) analysis set will be the primary anal ysis set for the efficacy endpoint; 
safety analysis set will be used for all safety assessments.  
12.2.1.1  Intent To Treat (ITT) 
The ITT population will include a ll subjects enrolled and eligi ble to receive study medication. 
The ITT population will be analyzed only for the purpose of sub ject disposition.  
12.2.1.2  Safety 
The safety population will include all ITT subjects who receive  at least one dose of the study 
drug. The safety population is a lso referenced as the modified ITT (mITT) population. The mITT 
population is the primary population for efficacy and safety ev aluations. 
12.2.1.3  PK population 
The PK population will include all safety population subjects w ho have had at least one PK 
sample drawn.  
12.2.1.4  Data Review for A nalysis Datasets 
After all the data have been verified/coded/entered into the da tabase, a review will be 
performed. The purpose of this review will be to define the ana lysis populations. The review 
will also check the quality of the data, identifying outliers, and making decisions on how to deal 
with problems in any data (e.g., missing values, withdrawals, p rotocol deviations). After the 
pre-analysis review, resolution of all issues and documentation  of all decisions, the database 
will be locked. 
12.3 Study Endpoints 
12.3.1  Efficacy Endpoint 
The Functional Assessment of Chronic Illness Therapy (FACIT) Fa tigue Scale (Version 4) is an 
exploratory efficacy endpoint for exploratory purposes only and  no formal analysis of efficacy 
endpoint is planned for this study (see Appendix 1 ).  
12.3.2  Safety Endpoints 
The primary safety endpoints of the study are the number and se verity of Treatment Emergent 
Adverse Events (TEAEs).  
12.3.3  Pharmacokinetic Endpoints  
The study endpoints are the plas ma concentrations of APL-2 and pharmacokinetics parameters 
of APL-2 following administration of the single SC dose in rele vant cohorts ( Section 12.9 ).  
12.4 Efficacy Analysis 
The FACIT Fatigue Scale is a 13-item Likert scaled instrument. The FACIT instrument results in a 
score with a range of 0 to 52. The measure is collected at Visi ts described in the Study Flow 
Chart. The analysis of baseline score and change from baseline by cohort and time point will be 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 62 of 72 evaluated. No imputation for any missing data will be planned. An exploratory efficacy analysis 
of the FACIT data and relevant PD markers will be presented. 
12.5 Safety Analysis  
All safety endpoints will be eva luated using the safety populat ion. No formal inferential 
statistics will be applied to the safety assessments. 
12.5.1  Total Exposure 
By-patient study drug exposure ( date/time of injection, injecti on site, injection volume) will be 
presented in a listing. 
12.5.2  Adverse Events 
Treatment emergent adverse events (TEAE) are defined as those A Es that develop or worsen 
after the first dose of study medication and up to 30 days beyo nd the last dose of study 
medication. The current version of Medical Dictionary for Regul atory Activities (MedDRA) will 
be used to classify all AEs.  
12.5.2.1  Adverse Events Summary 
A by-subject TEAE data listing, including verbatim term, prefer red term, treatment, severity, 
and relationship to treatment will be provided. Serious adverse  events (SAEs), adverse events of 
special interest (as defined in Section 11.5), and details of s ubjects withdrawing due to adverse 
events will also be listed.  
AEs will be tabulated as a total population and by treatment gr oup. For Cohort 1 and Cohort 2, 
reported tables will also consider the dosing phase for the AE.  The following will be tabulated: 
1. Topline summary of Adverse Events, tabulating the number of TEA Es, treatment related 
AEs, Serious AEs, AEs of special  interest, injection site react ions, and adverse events 
leading to discontinuation  
2. TEAEs by SOC and preferred term  
3. TEAEs regarded as possibly/proba bly related to study drug by SO C and preferred term 
4. TEAEs and Serious AEs by maximum  severity, and by SOC and prefe rred term  
5. Adverse events of special intere st by maximum severity and rela tionship to study drug  
12.5.3  Clinical Laboratory Tests 
All laboratory endpoints will be summarized in listings. In add ition, laboratory values that are 
above or below the reference range will be identified in the li stings.  
12.5.4  Vital Signs 
Vital signs will be listed for each subject and time point. Any  Investigator determined potential 
clinically significant findings  will be identified and listed.  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 63 of 72 12.5.5  ECGs 
ECG results will be classified using frequency counts for norma l, abnormality that is not 
clinically significant (NCS), a nd clinically sign ificant abnorm ality (CS) by cohort and time point of 
collection. ECGs results will be listed for each subject and ea ch time point. Any Investigator 
determined potential clinically significant changes will be ide ntified and listed.  
12.6 Handling of Dropouts and/or Missing Data 
No imputation of missing data for early terminations will be pe rformed.  
12.7 Examination of Subgroups 
Due to the potentially small sample size in any subgroup analys es performed will use 
descriptive statistics only; no tests of hypotheses will be per formed. 
12.8 Enumerated Data 
Physical Examination and changes  in physical examinations findi ngs after baseline will be 
reported in a listing. 
Concomitant medications will be listed by treatment and coded u sing the most current WHO 
drug dictionary. 
Medical history findings will be c oded using latest MedDRA dict ionary and listed by subject. 
12.9 Pharmacokinetic Analysis 
All subjects dosed and having any measurable serum concentratio n of study drug will be 
included in the PK data set. 
The individual plasma concentration profiles of APL-2 after sin gle dose phase (for Cohorts 1 and 
2) and multiple dose phase (for all cohorts) will be listed and  plotted. 
Where possible, in Cohort 1 and Cohort 2, PK parameters for APL -2 will be computed from the 
individual serum concentrations- time data during the single dos e phase, using actual sample 
times. PK parameters will be listed, but not summarized.  
 
AUC 0-t The area under the serum concentration versus time curve, from time 0 
to the last measurable concentration  prior to the start of multiple 
dosing , as calculated by the linear trapezoidal method when 
concentrations are increasing and the logarithmic trapezoidal m ethod 
when concentrations are decreasing. 
Cmax Maximum observed serum concentration.  
tmax Time of the maximum measured serum concentration. If the maximu m 
value occurs at more than one time point, t max is defined as the first 
time point with this value.  
Additional PK analyses may be performed. Any analyses or presen tations will be outlined in the 
Statistical Analysis Plan. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 64 of 72 12.10  Pharmacodynamic Analysis 
All subjects dosed and having any measurable PD data will be in cluded in the PD data set. 
PD parameters include Lactate De hydrogenase (LDH), Haptoglobin,  Hemoglobin, serum levels 
of CH50, AH50, and C3, and clonal distribution of PNH cells. Th ese data will be listed by subject 
and cohort along with changes from baseline and percent changes  from baseline. Individual 
changes and percent changes from baseline will be plotted again st assessment. 
Red blood cell transfusion data will also be listed by subject and cohort. 
12.11  Antigenicity Analysis 
APL-2 antigenicity will be assaye d in a GLP-compliant manner us ing a validated direct 
ELISA-based method incorporating  a mouse monoclonal antibody sp ecific for PEG as a positive 
control that is capable of detecting extremely low amounts of a nti-PEG and APL-2 antibodies, 
typically in the sub-μg/ml concentration range. This anti-PEG m onoclonal antibody will be 
included as positive controls on every ELISA test plate run in these studies. 
12.12  Interim Analysis 
As mentioned in Section 9.3, a s afety review committee will be formed to review 
safety/tolerability, PK and PD data between cohorts. Preliminar y PK analysis may also be 
performed to reconsider sampling time points as the study progr esses. 
When all subjects have completed (or discontinued) Part 2A or P art 3 if they didn’t enter Part 
2A, the data collected up to and including these study visits w ill be reported. Further reports 
may be prepared with each report containing  cumulative informa tion. These reports will be 
performed on data that will have been fully checked and conside red as final. Any changes to 
the data previously reported w ill be fully auditable and discus sed in the subsequent reports. 
12.12.1  Safety (optional) 
At the Sponsor’s request, safety  tables, figures, and data list ings may be presented to the 
sponsor’s consultants for the pu rposes of planning the next Pha se 1 or initial Phase 2 studies 
prior to database lock. These in terim analyses will be performe d on data that will be edit-
checked and monitored. 
A safety programmer and a biosta tistician will prepare safety t ables, figures, and data listings. 
13. ADMINISTRATIVE CONSIDERATIONS 
13.1 Direct Access to Source Data/Documents 
The Investigator must maintain, at all times, the primary recor ds (i.e., source documents) of 
each subject’s data for data verification. Examples of source d ocuments are medical records, 
laboratory reports, study drug records, and eCRFs that are used  as the source. 
The Investigator will permit trial-related monitoring, audits, and inspections by the Sponsor 
and/or its’ designee, IRB/IEC, a nd the regulatory agencies at a ny time during the study. The 
Investigator will ensure that the auditor is allowed direct acc ess to the source data, medical 
records, eCRFs, and the Site’s r egulatory file for the study an d any other pertinent information.  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 65 of 72 13.2 Quality Control and Quality Assurance 
This study is to be performed in full compliance with the proto col, Good Clinical Practices (GCP), 
and applicable regulatory requirements. The Investigator, Spons or and/or its’ designee are 
responsible for ensuring that the study staff receive appropria te training on the protocol, study 
procedures and any other relevant information.  
Quality assurance and quality co ntrol systems are implemented a nd maintained using written 
Investigative site, Sponsor and/ or designee Standard Operating Procedures (SOPs) to ensure 
that the study is conducted and data are generated, documented (recorded), and reported in 
compliance with the protocol, GCP,  and the applicable regulator y requirement(s) and local 
laws, rules, regulations. 
Quality control (QC) checks will be applied at each stage of da ta handling (e.g. edit checks) to 
ensure that all data are reliable and have been processed corre ctly.  
13.2.1  Monitoring 
On-site monitoring will be performed by the Sponsor’s designee for the duration of the study. 
The monitor will ensure that the study is conducted, recorded a nd reported in accordance with 
the protocol, SOPs, GCP, and the applicable regulatory requirem ents. The monitor will verify 
the accuracy and completeness of the eCRF entries, source docum ents, and other study-related 
records against each other. The Investigator will provide direc t access to source 
data/documents for study-related  monitoring. It is important th at the Investigator and the staff 
are available at these visits. The monitor will record the date  of each visit together with a 
summary of the status and progress of the study. Proposed actio ns will be documented in 
writing to the Investigator. 
13.3 Ethics 
13.3.1  Ethical Conduct of the Study 
This research will be carried out in accordance with the protoc ol, US Code of Federal 
Regulations, GCP, 21 CFR Parts 5 0, 56, and 312, the ethical pri ncliples set forth in the 
Declaration of Helsinki, and the ICH harmonized tripartite guid eline regarding GCP (E6 
Consolidated Guidance, April 1996). 
13.3.2  Institutional Review Board/Ethic Committee 
The study protocol, any amendmen ts to the protoc ol, informed co nsent form, the Investigator’s 
Brochure, and other study specific information will be reviewed  and approved by the IRB/IEC. 
The study will not be initiated u ntil the IRB/IEC has approved the protocol or a modification 
thereof. All records pertaining to IRB/IEC submission and appro val should be kept in the site’s 
regulatory files and Sponsor’s Trial Master File (TMF). 
The IRB/IEC must be constituted and operate in accordance with the principles and 
requirements described in the US Code of Federal Regulations (2 1 CFR Part 56) and/or ICH 
Guidelines, or other local regulations as deemed appropriate. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 66 of 72 13.3.3  Subject Information and Consent 
The Investigator is responsible for obtaining an informed conse nt. A written informed consent, 
in compliance with the US Code of Federal Regulations (21 CFR P art 50), must be obtained from 
each subject prior to screening and enrollment or performing an y study related procedures. 
The purpose of the study, the procedures to be carried out and the potential hazards will be 
described to the subjects in non-technical terms. The subject w ill be given sufficient time to 
consider the study’s implication s before deciding to participat e in the study. The subject and/or 
legal guardian will be required to sign and date an Informed Co nsent Form (ICF) and will be 
assured that they may withdraw from the study at any time witho ut jeopardizing their medical 
care. The Investigator shall retain the original, signed inform ed consent for study participation 
in the subject’s medical record and shall provide the subject a nd/or legal guardian with a copy 
of the signed consent. 
If there are any changes/amendments to the approved protocol, w hich may directly affect the 
subject’s decision to continue participation in the study, the ICF shall be amended to 
incorporate the changes to the protocol and the subject must re -sign the IRB/IEC approved 
amended ICF. 
13.3.4  Confidentiality  
Confidentiality of subjects information must be maintained in a ccordance with the Health 
Insurance Portability and Accountability Act (HIPAA) Privacy Ru le-Final Modification (45 CFR 
Parts 160 and 164). 
13.3.5  ClinicalTrials.gov  
This study will be listed with C linicalTrials.gov, as required.  
13.3.6  Termination of Study 
The Sponsor reserves the right to suspend or discontinue this s tudy for administrative and/or 
safety reasons at any time. The investigator reserves the right  to discontinue dosing subjects at 
any time for safety reasons. 
13.4 Data Handling and Record Keeping 
The Investigator must maintain all documentation related to thi s study. All essential documents 
(as defined in the ICH Guideline E6) and the data generated in connection with this study, 
together with the original copy of the final report, will be re tained for at least 5 years after the 
last approval of a marketing application in an ICH region and u ntil there are no pending or 
contemplated marketing applications in an ICH region or at leas t 5 years have elapsed since the 
formal discontinuation of clinical development of the investiga tional product. These documents 
should be retained for a longer period if required by the appli cable regulatory requirements or 
by an agreement with the Sponsor.  
It is the responsibility of the Sponsor to inform the Investiga tor/Institution as to when these 
documents no longer need to be retained. 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 67 of 72 13.5 Protocol Amendments 
Any amendments to the study proto col deemed necessary as the st udy progresses will be 
discussed between Sponsor and the Investigator. The Investigato r will not implement any 
changes to the protocol without an agreement by the Sponsor and  prior review and documented 
approval/favorable opinion from the IRB/IEC of an amendment, ex cept where necessary to 
eliminate immediate hazards to study subject or when the change s involve only logistical or 
administrative aspects of the study ( e.g., change in staff, telephone numbers). 
Changes resulting in amendments will be made jointly between th e Sponsor and the 
Investigator and must be confirme d in writing. Amendment(s) wil l be approved and signed off 
in the same way as the protocol.  
13.6 Report Format 
According to the ICH Harmonized Tripartite Guideline (Organizat ion of the Common Technical 
Document for the Registration of Pharmaceuticals for Human Use M4 and the ICH M2 Expert 
Working Group), the final report will be written according to t he ICH E3 Guideline (Structure 
and Content of Clinical Study Reports). 
13.7 Finance and Insurance 
Finance and insurance will be a ddressed in a Clinical Trial Agr eement between the 
Investigator/Institution. 
13.8 Publication Policy 
The data generated for this study are considered confidential i nformation and are the property 
of the Sponsor. All study information provided to the Investiga tor and Site personnel by the 
Sponsor shall not be published or disclosed to a third party wi thout the prior written consent of 
the Sponsor.  
After the completion of the study, the data may be reported at a scientific meeting and/or 
submitted for publication in a scientific journal with the prio r written consent of the Sponsor. 
The Sponsor must be given at a minimum 30 days to review the ma terials to be presented at a 
scientific meeting and/or for p ublication in a scientific journ al.  
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 68 of 72 14. REFERENCES 
Note : A copy of the publications by DeZern (2013), Ivens (2013) and Rudmann (2013) 
referred to in this document is included in Item 10 and on the CD attached to the original 
IND submission. 
 
1. Schrezenmeier et al. Baseline characteristics and disease burde n in patients in the 
International Paroxysmal Nocturnal Hemoglobinuria Registry. Hae matologica, 2014, 99 
(5), p. 922-929. 
2. Hillmen P, et al. Long-term effect of the complement inhibitor eculizumab on kidney 
function in patients with paroxy smal nocturnal hemoglobinuria. Am. J. Hematol., 2010,  
85, p.553–559. 
3. DeZern AE, Dorr D, and Brodsky, RA. Predictors of Hemoglobin Re sponse to Eculizumab 
Therapy in Paroxysmal No cturnal Hemoglobinuria, Eur J Haematol. , 2013, 90(1), p.16-24 
4. Apellis Pharmaceuticals, Inc. APL -2. Investigator’s Brochure. V ersion 5 April 2016. 
5. FDA Guidance for Industry: Estimating the Maximum Safe Starting  Dose in Initial Clinical 
Trials for Therapeutics in Adult Healthy Volunteers. July 2005.  Available online:  
http://www.fda.gov/downloads/Drug s/GuidanceComplianceRegulatory Information/Gui
dances/ucm078932.pdf   
6. FDA Guidance for Industry: Toxici ty Grading Scale for Healthy A dult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials. Sept ember 2007. Available 
online: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCom plianceRegulator
yInformation/Guidances/Vaccines/ucm091977.pdf 
7. FDA Guidance for Industry and In vestigators:  Safety Reporting Requirements for INDs 
and BA/BE Studies-Small Entity Com pliance Guide. December 2012.  Available online: 
http://www.fda.gov/downloads/Drug s/GuidanceComplianceRegulatory Information/Gui
dances/UCM332846.pdf 
8. Ivens, I. A., Baumann, A., McDonald, T. A., Humphries, T. J., M ichaels, L. A., and Mathew, 
P. (2013). PEGylated therapeutic proteins for haemophilia treat ment:  a review for 
haemophilia caregivers. Haemophilia 19:  11-20 
9. Rudmann, D.G., Alston, J.T., Han son, J.C., and Heidel, S. (2013 ). High molecular weight 
polyethylene glycol cellular distribution and PEG-associated cy toplasmic vacuolation is 
molecular weight dependent and does not require conjugation to proteins. Toxicol 
Pathol 41:  970-983. 
10. 2016 Adult Immunization Schedule was approved by the Centers fo r Disease Control 
and Prevention’s (CDC). Fedrua ry 2016. Accessed on August 1st 2016. 
http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-com bined-
schedule.pdf 
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 69 of 72 15. APPENDIX 1: FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY 
(FACIT) FATIGUE SCALE 
 
FACIT Fatigue Sc ale (Version 4) 
Below is a list of statements that other people with your illne ss have said are important . Please 
circle or mark one number per line to indicate your response as  it applies to the past 7 days. 
 
 
   Not at 
all A little 
bit Some-
what Quite 
a bit Very 
much  
 
HI7 I feel fatigued ............................................... ................. ....................... 0 1 2 3 4 
HI12 I feel weak all over .......................................... ...................... ............... 0 1 2 3 4 
An1 I feel listless (“washed out”) ................................ ................................ 0 1 2 3 4 
An2 I feel tired .................................................. .............. ............................ 0 1 2 3 4 
An3 I have trouble starting things because I am tired ................................ 0 1 2 3 4 
An4 I have trouble finishing things because I am tired ............................... 0 1 2 3 4 
An5 I have energy ................................................. ............... ....................... 0 1 2 3 4 
An7 I am able to do my usual activities ........................... ............................ 0 1 2 3 4 
An8 I need to sleep during the day ................................ ............................. 0 1 2 3 4 
An12 I am too tired to eat.......................................... ...................... ............. 0 1 2 3 4 
An14 I need help doing my usual activities ......................... ....... ................... 0 1 2 3 4 
An15 I am frustrated by being too tired to do the things I want to d o .........  
0  
1  
2  
3  
4 
An16 I have to limit my social activity because I am tired ............................ 0 1 2 3 4 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 70 of 72 FACIT-Fatigue Subscale Scoring Guidelines  (Version 4)  
 
Instructions:* 1. Record answers  in "item response" column. If missing, mark with an X 
2. Perform reversals as indicated,  and sum individual items to obtain a score. 
3. Multiply the sum of the item scores by the number of items i n the subscale, 
then divide by the number of items answered. This produces the subscale score. 
4. The higher the score, the better the QOL.  
 
Subscale        Item Code       Reverse item?     Item response       Item Score  
 
FATIGUE  HI7       4 - ________  =________ 
SUBSCALE  HI12  4 - ________  =________ 
      An1  4 - ________  =________ 
An2  4 - ________  =________ An3  4 - ________  =________ 
An4  4 - ________  =________ 
An5  0 + ________  =________ 
An7  0 + ________  =________ 
An8  4 - ________  =________ An12  4 - ________  =________ 
An14  4 - ________  =________ 
An15  4 - ________  =________ 
An16  4 - ________  =________ 
 
Sum individual item scores: ________ 
Multiply by 13: ________ 
Divide by number of items 
answered:  ________ (Fatigue Subscale Score)  Score range: 0-52 
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 71 of 72 *For guidelines on handling missing data and scoring options, p lease refer to the Administration 
and Scoring Guidelines in the manual or on-line at www.facit.org . 
NOTE: The FACIT and all related works are owned and copyrighted  by, and the intellectual 
property of David Cella, Ph.D. Permission for use of the FACIT- FATIGUE questionnaire is 
obtained by contacting Dr. Cella at information@facit.org 
  
 
 APL-2 
Ascending Dose / First in Human / PNH Add-on to SOC 
Apellis Pharmaceuticals, Inc.  Protocol Number: APL-CP0514 
V4.0 Amendment 7 
Effective: 15-JUN-2017  
PROT_  APL-CP0514_Amendment 7_June 15th, 2017 -  CONFIDENTIAL Page 72 of 72 16. APPENDIX 2: ASSESSMENT OF LOCAL INJECTION SITE REACTIONS 
Local injection site reactions will be rated according to the F DA Guidance for In dustry: Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrol led in Preventative Vaccine 
Clinical Trials (Sep 2007)3 as follows: 
 
Local Reaction  Mild 
(Grade 1) Moderate 
(Grade 2) Severe 
(Grade 3) 
Pain  Does not interfere with 
activity  Repeated use of non -
narcotic pain reliever 
> 24 hours or interferes 
with activity  Any use of narcotic pain 
reliever or prevents 
daily activity  
Tenderness  Mild discomfort to touch Discomfort with 
movement  Significant discomfort at 
rest 
Erythema/Redness*  2.5 – 5 cm 5.1 – 10 cm > 10 cm  
Induration/Swelling** 2.5 – 5 cm and does not 
interfere with activity  5.1 – 10 cm or interferes 
with activity  > 10 cm or prevents 
daily activity  
* In addition to grading the measured local reaction at the great est single diameter, the measurement should be 
recorded as a continuous variable. 
** Induration/swelling should be evaluated and graded using the  functional scale as well as the actual 
measurement. 
 
 